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ABSTRACT
ACTIVATABLE FLUOROPHORES FOR THE MOLECULAR IMAGING OF
CYTOSOLIC PHOSPHOLIPASE A2 IN BREAST CANCER
Michael Gerard Chiorazzo
E. James Delikatny, Ph.D.

Breast cancer is the most commonly diagnosed cancer in women and the number two
cause of cancer associated death. Surgery is the first line of defense in treating breast
cancer and the success of surgery has been shown to predict the probability of cancer
reoccurrence. Near Infrared (NIR) fluorescence guided surgery offers the potential to
increase the accuracy of surgical resection by the use of fluorescence imaging agents
targeted towards cancer. Cytosolic Phospholipase A2 (cPLA2) activity is enhanced in
triple negative breast cancer and is associated with resistance to therapy in luminal-like
cancers. The goal of this work is to develop activatable fluorophores targeted towards
cPLA2 and evaluate their use for the molecular imaging of breast cancer in order to
determine their potential as contrast agents for NIR fluorescence guided surgery. A
series of tricyclic fluorophores were caged through esterification with fatty acids.
Arachidonic acid was utilized to generate cPLA2 selective probes and palmitic acid was
used to generate control probes. In vitro, probes were shown to activate in the presence
of purified PLA2 and results were used to identify the most promising probe: DDAO
arachidonate. Cellular fluorescence spectroscopy and microscopy showed DDAO
arachidonate activated in breast cancer cell lines expressing cPLA2, where control probe
did not. Modulation of cPLA2 activity through inhibition, induction, and genetic
v

knockdown, resulted in corresponding changes in fluorescence generation. In a panel of
breast cancer cell lines, cPLA2 expression, varied based on molecular subtype and
correlated with DDAO arachidonate activation. Finally, DDAO arachidonate, when
painted onto human triple negative tumor mouse xenografts, resulted in selective
activation of tumor but not surrounding healthy tissue. Together, these results indicate
DDAO arachidonate is a useful agent for measuring cPLA2 activity in both breast cancer
cells and tumors and may offer the potential to aid in the fluorescence guided surgery of
triple negative breast cancer.
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CHAPTER 1: Introduction
1.1

Breast Cancer
In women, breast cancer is the most frequently diagnosed cancer and the second

highest cause of cancer related death (DeSantis et al. 2014). Breast cancer has been
shown to be not one disease, but an umbrella term for numerous cancer subtypes.
Extensive study on the molecular basis of breast cancer subtypes has led to the
elucidation of varying genetic signatures. This has driven the development of molecular
based therapeutics, which targets these genetic signatures in each subtype. The growth of
targeted therapeutics in addition to increased screening of the general population has
likely been the cause of decreased mortality rates in breast cancer patients (Berry et al.
2005). Despite this, surgical resection through either mastectomy or breast conserving
surgery in combination with radiation therapy remains the standard for primary treatment
(DeSantis et al. 2014). The accuracy of surgery, as defined by the presence of positive
margins in tissue histology, is a significant predictor for local recurrence and metastasis,
suggesting complete removal of the primary tumor is necessary for enhancing the
probability of relapse free survival (Singletary 2002).
Estrogen receptor (ER) positive is the most frequently diagnosed form of breast
cancer (Haque et al. 2012). Commonly referred to as luminal-like, cancers expressing
estrogen receptor can be classified as luminal A or luminal B. Luminal A has the most
favorable prognosis of all breast cancer subtypes and is associated with the highest
probability of relapse free and overall survival (Prat and Perou 2011). It is generally
defined as having high levels of ER and/or progesterone receptor (PR) with no expression
1

of the HER2/Neu oncogene, low Ki67 staining (a standard marker of proliferation), and a
low histological grade (Eroles et al. 2012). For breast cancer, histological grade is
determined in accordance with the Nottingham grading system which evaluates tumors
based on tubule formation, nuclear grade, and mitotic rate (Edge and Compton 2010).
Luminal B breast cancer has high amounts of ER and/or PR along with either expressing
the HER2/Neu oncogene or having high staining for Ki67 with a high histological grade.
Unlike luminal A, luminal B breast cancer has lower rates of relapse free and overall
survival (Prat and Perou 2011). In addition to surgery and radiation therapy, common
adjuvant treatment of luminal-like breast cancer consists of hormonal therapy with
selective estrogen receptor modifiers (SERMs). One of the most commonly used SERMs
is tamoxifen, a prodrug whose biologically active metabolites result in competitive
antagonism of ER (Osborne 1998).
HER2-type breast cancer is defined as expressing the HER2/Neu oncogene
without expression of ER or PR (Eroles et al. 2012). The HER2/Neu gene encodes for a
transmembrane tyrosine kinase receptor that falls within the epidermal growth factor
receptor (EGFR) family (Ross et al. 2003). Activation of EGFR enhances homo and
hetero-dimerization resulting in autophosphorylation and the initiation of various major
biological signaling cascades (Normanno et al. 2006). Overexpression of HER2/Neu has
been shown to occur in 20-30% of breast cancers and has fueled the development of antiHER2/Neu therapies (Slamon et al. 1987). Most notable is the monoclonal antibody,
trastuzumab, which is selective for the extracellular portion of the HER2 transmembrane
protein (Hudis 2007). The anti-cancer activity of trastuzumab may result from a
2

combination of mechanisms including decreasing HER2 dimerization, increasing
receptor endocytosis and subsequent degradation, preventing the cleavage and release of
the extracellular domain, and immune activation resulting in cancer cell death
(Valabrega, Montemurro, and Aglietta 2007). Regardless, significant efficacy has been
shown in HER2-type breast cancer patients when used in combination with traditional
chemotherapeutics (O'Sullivan et al. 2015).
Basal-like is a subtype of breast cancer which does not have elevated ER, PR, or
HER2/Neu. Because of this, it is often referred to as triple negative breast cancer and has
the lowest probability of relapse free and overall survival (Eroles et al. 2012). No
molecular based therapeutics exist for this subtype and only traditional chemotherapy in
addition to surgery and radiation therapy is possible. Basal-like breast cancer has a high
response rate to pre-surgical neoadjuvant chemotherapy (Lehmann et al. 2011). Despite
this, high rates of recurrence and metastasis result in lower probability of relapse free and
overall survival, with less than 30% of basal-like patients surviving 5 years.
A further complication to this model of genetic variation and subsequent
treatment of breast cancer is the increasing understanding of tumor heterogeneity.
Heterogeneity within breast cancer can arise both spatially, in which several populations
of cells with varying genetic signatures are present within the same tumor, or temporally,
in which the genetic signatures of cells change with time in the primary tumor and
metastatic lesions (Zardavas et al. 2015). Certain basal-like tumors have been shown to
contain distinct populations of luminal-like progenitors (Lim et al. 2009). In addition,
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differences in expression of ER, PR, and HER2 have been seen between primary tumor
and metastatic lesions (Aurilio et al. 2014).
It is likely that tumor heterogeneity, in addition to the limited number of
molecular therapeutics, contributes to the problem of breast cancer resistance,
reoccurrence, and metastasis. Because of therapeutic limitations, surgical resection
through either mastectomy or breast conserving surgery in combination with radiation
therapy remains the primary treatment for breast cancer, being performed in 95% of
cases. Improvement of surgical resection efficiency would likely have a high benefit on
survival.
Near Infrared (NIR) fluorescence guided surgery has recently emerged as a
powerful technique to aid surgeons during tumor resection. By administering
fluorophores, which either accumulate or activate specifically in cancerous tissue,
surgeons can use fluorescence as a guide for the discernment of tumor margins (Nguyen
and Tsien 2013). To date, several studies have shown the ability of NIR fluorescence
guided surgery to improve surgical resections in patients (Shinoda et al. 2003, van Dam
et al. 2011, Day et al. 2013, Stummer et al. 2006, Keating et al. 2016, Judy et al. 2015).
However, the pool of fluorescence contrast agents under study remains small and the
most well studied agents rely primarily on the enhanced permeability and retention effect
(EPR) of tumors. In order to expand the capabilities and efficiency of this technique,
new contrast agents targeted towards distinct molecular features of cancer are urgently
needed.

4

1.2

Phospholipases
Phospholipases are a class of enzyme responsible for the catabolism of

phospholipids within biological membranes. First discovered for their role as a lytic
agent in snake venom, phospholipases have since been shown to have numerous
biological functions including digestion, membrane re-modeling (necessary for cell
division, motility, and vesicular trafficking), and the generation of bioactive signaling
molecules (Burke and Dennis 2009, Rocha et al. 2014). In cancer, increased cell division
through membrane remodeling along with the production of bioactive signaling
molecules that promote cancer progression have been linked to phospholipase activation.

Figure 1.1. Overview of phospholipase activity. PLA1 and PLA2 cleave at the sn-1 and sn-2 ester bond
respectively to generate lysophosphatidic acid and a free fatty acid. PLC cleaves at the glycerol-phosphate
bond to release phosphatidic acid and a free head group. PLD cleaves at the head group-phosphate bond to
generate DAG and a phosphorylated head group.
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Phospholipases are grouped into four major categories based on the location in
which they hydrolyze phospholipids (Figure 1.1). Phospholipase D hydrolyzes the bond
linking the head group to the phosphate moiety releasing a free head group in addition to
phosphatidic acid. Phospholipase D has been found elevated in several cancers including
breast, colon, gastric, and kidney (Park et al. 2012). It is generally thought to promote
cancer progression through the activation of RAS and mTOR by phosphatidic acid (Zhao
et al. 2007, Fang et al. 2001). Phospholipase C is perhaps the most well-known
phospholipase for its role in signaling. Phospholipase C hydrolyses the glycerophosphate
bond of phospholipids releasing diacylglycerol (DAG) and a phosphorylated head group.
When phospholipase C acts on phosphatidylinositides, inositol-1,4,5-triphosphate (IP3) is
released. IP3 and DAG have been extensively studied for their role in signaling and in
relation to cancer. IP3 leads to release of calcium from intracellular stores leading to
modulation of numerous enzymes which are dependent on calcium binding (Berridge
2009). DAG is the principal activator of protein kinase C (PKC), which has been shown
to promote the progression of cancer (Griner and Kazanietz 2007). Finally,
phospholipase A1 and A2 (PLA1 and PLA2, respectively) are responsible for the release
of a lysophospholipid and a free fatty acid from, respectively, either the sn-1 or sn-2
position of the glycerol backbone. Lysophospholipids are potent activators of cancer and
can stimulate mobilization and subsequent invasion (Xu et al. 1995). Free fatty acids can
be stored in lipid droplets, recycled into biological membranes, metabolized via beta
oxidation, or used to synthesize downstream signaling molecules (Boren and Brindle
2012, Delikatny et al. 2011). Arachidonic acid release serves as the precursor to
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eicosanoid signaling molecules, which have been shown to have numerous roles in
cancer progression (Wang and Dubois 2010).
PLA2 can be further sub-classified into sixteen groups, each representing PLA2
enzymes with distinct biological functions. Secreted phospholipase A2 (sPLA2)
enzymes (which include groups I, II, III, V, and X) are found in the extracellular space,
are the largest family of phospholipases, and the first to be discovered. Though large in
number, they are smallest in size, typically ranging from 14-18 kDa (with the exception
of group III). sPLA2 enzymes are dependent on calcium for activity and serve a range of
functions including digestion, activity in inflammatory processes, and microbial
protection (Burke and Dennis 2009). sPLA2 has been shown to play a role in several
diseases including rheumatoid arthritis, atherosclerosis, and cancer (Dennis et al. 2011).
Calcium independent phospholipase (iPLA2, group VI) is an intracellular PLA2
which does not require calcium for its activity (Burke and Dennis 2009). iPLA2β is the
most well studied iPLA2 family member. Due to its calcium independent actions it has
been long thought to function in homeostatic membrane remodeling (Winstead, Balsinde,
and Dennis 2000). Recently it has been suggested that iPLA2 may also be active in
several signaling processes. iPLA2 has been implicated in the development of diabetes,
Barth syndrome, and NBIA/neuroaxonal dystrophy (Dennis et al. 2011).
Platelet activating factor-acetyl hydrolase (PAF-AH, group VII) acts on PAF to
release acetate from the sn-2 position. PAF-AH is a secreted enzyme that associates with
LDL and HDL in the human plasma (Tjoelker et al. 1995). Increased PAF-AH is
7

associated with an increased risk of coronary disease, stroke, and mortality (Oei et al.
2005). Lysosomal phospholipase A2 (LPLA2) (group XV) localizes to lysosomal
compartments of cells where it acts to degrade lysosomal phospholipids. LPLA2 is
highly expressed in alveolar macrophages (Abe et al. 2004). Adipose-specific
phospholipase A2 (group XVI) is expressed to high levels in white adipose tissue
(Duncan et al. 2008). Adipose-specific phospholipase A2 has been shown to also possess
PLA1 activity and functions to release stored fatty acids for energy conversion through
beta oxidation.
Cytosolic phospholipase A2 (cPLA2, group IV) is a class of phospholipases that
are primarily considered signaling enzymes. Like iPLA2, cPLA2 is an intracellular
phospholipase and resides in the cytosol until activated (Dennis et al. 2011). cPLA2α,
the most studied isoform, was first found in platelets and neutrophils, but is now known
to be ubiquitously expressed in all mammalian tissue. This 85 kDa protein contains a C2
calcium binding domain and a catalytic domain containing a unique catalytic dyad
instead of the catalytic triad seen in α/β hydrolases (Dessen et al. 1999). Unlike other
PLA2 enzymes, cPLA2α displays substrate specificity for arachidonic acid at the sn-2
position (Murakami et al. 2011). Since the discovery of cPLA2α, two additional human
isoforms have been found (along with three murine isoforms). cPLA2β is a ubiquitous
phospholipase, and contains a C2 domain and a catalytic domain similar to cPLA2α.
Unlike cPLA2α, cPLA2β has relatively low substrate specificity and general
phospholipase activity. cPLA2γ is expressed to a high degree in heart and skeletal
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muscle, has low substrate specificity, and lacks a C2 domain allowing it to act
independent of calcium (Dennis et al. 2011).
1.3

cPLA2 and Cancer
cPLA2α, henceforth referred to as cPLA2, is activated during calcium release

from cytosolic stores. The binding of calcium to the C2 domain of cPLA2 results in
translocation to the perinuclear membrane where it acts upon arachidonic acid-containing
phospholipids. In addition to calcium, cPLA2 activity can be enhanced by
phosphorylation through mitogen-activated protein (MAP). Ser505 phosphorylation
promotes membrane binding of hydrophobic residues surrounding the active site. This
allows for cPLA2 to remain bound to the membrane and active after the cytosolic
calcium concentration returns to baseline (Das et al. 2003). An additional residue, Ser727
is targeted by a heterotetramer (A2t) of p11 and annexin A2, which when bound to
Ser727 disrupts cPLA2 membrane binding and inhibits activity (Tian et al. 2008).
Phosphorylation of Ser727 prevents targeting by the inhibitory A2t tetramer and allows
full activation of cPLA2. In addition, phosphorylation of Ser515 by calmodulindependent kinase II has also been shown to result in cPLA2 activation (Muthalif et al.
2001). Independent of phosphorylation, several other associations result in the retainment
of cPLA2 on the membrane. Phosphatidylinositol 4,5-bis phosphate (PIP2) has been
found to bind residues within the catalytic domain and promote cPLA2 activity (Tucker
et al. 2009). Finally, ceramide-1-phosphate (C1P) has been found to be required for
translocation of cPLA2 through association with a β-groove in the C2 domain (Lin et al.
1993, Mosior, Six, and Dennis 1998, Subramanian et al. 2005, Lamour et al. 2009).
9

cPLA2 functions as a signaling agent due to its ability to release free arachidonic
acid. Free arachidonic acid is an important central mediator in inflammatory and
replicative processes. Arachidonic acid can be acted upon by cytochrome P450 (CYPs),
lipoxygenase, or cyclooxygenase to generate prostaglandins and eicosanoids, a large
family of bioactive molecules involved in autocrine and paracrine signaling (Figure 1.2)
(Wang and Dubois 2010). In addition to homeostatic maintenance, eicosanoids are
involved in a wide range of functions including vasodilation and constriction of vascular
smooth muscle, aggregation and declumping of platelets, contraction of uterine smooth
muscle, bone resorption, ovulation, pain response, fever generation, and inflammation
(Funk 2001). Dysregulation of eicosanoids has been implicated in several diseases
including rheumatoid arthritis, hypertension, atherosclerosis, and cancer.

Figure 1.2. Eicosanoid Signaling Pathway.
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CYPs are best known for their involvement in the detoxification of compounds in
the liver. Blockage of these enzymes can result in the prolonged half-life of drugs,
resulting in increased delivery of many compounds, including anticancer drugs
(Panigrahy et al. 2010). In contrast, certain anticancer prodrugs rely on the actions of
CYPs and increasing their activity may increase efficacy (Lu, Chen, and Waxman 2009).
In addition, the action of CYPs on endogenous substrates such as arachidonic acid are
thought to play a role in tumor progression (Nebert and Dalton 2006). Arachidonic acid
metabolism through CYPs occurs through either the -hydroxylase pathway, resulting in
the formation of hydroxyeicosatetraenoic acids (HETEs), or the epoxygenase pathway,
resulting in formation of epoxyeicosatrienoic acids (EETs) (Panigrahy et al. 2010). 20HETE, the primary metabolite of the -hydroxylase pathway, has pro-inflammation and
pro-angiogenic associations. Inhibition of CYPs in the 20-HETE pathway has been
shown to reduce tumor growth in triple negative breast cancer, mouse tumor xenografts
(Borin et al. 2014). EETs have also been shown to promote angiogenesis and have a role
in epithelial cell proliferation (Harris et al. 1990). CYP J2J, involved in EET synthesis
has been found to be elevated in 77% of carcinomas (Jiang et al. 2005).
Lipoxygenase activity results in the formation of HETEs and leukotrienes, which
have been shown to have several roles in cancer (Wang and Dubois 2010). LTB4 has
been shown to be increased in colon and prostate cancer (Larre et al. 2008, Dreyling et al.
1986). Pancreatic cancer has increased LTB4 receptors, and administration of LTB4
increases growth of pancreatic cancer cells (Hennig et al. 2002). LTA4 hydrolase has
been shown to be elevated in esophageal cancer through analysis of patient tissue (Chen
11

et al. 2003). Inhibition of LTA4 hydrolase in a rat model of esophageal cancer resulted
in reduced cancer growth (Chen et al. 2003).
The cyclooxygenase pathway is the most well studied pathway for arachidonic
acid metabolism in relation to cancer. Cyclooxygenase has two isoforms (COX-1 and 2), with COX-1 being considered a constitutively active housekeeping enzyme whereas
COX-2 is inducible in response to various stimuli (Simmons, Botting, and Hla 2004). In
cancer, overexpression of COX-2 has been shown in numerous cancers including colon,
prostate, head and neck, lung, cervical, and breast cancer (Eberhart et al. 1994, Gupta et
al. 2000, Khuri et al. 2001, Kulkarni et al. 2001, Lin et al. 2002, Subbaramaiah et al.
2002). Inhibition of cyclooxygenases with nonsteroidal anti-inflammatory drugs
(NSAIDs) has shown some ability to prevent and treat cancer (Thun, Henley, and Patrono
2002).
Cyclooxygenase acts on arachidonic acid to generate prostaglandin H2, which is
then further converted into the prostaglandins and thromboxanes. Prostaglandins have
been shown to have varying activity in cancer progression. PGE2 is well known for its
association with cancer, promoting proliferation, angiogenesis, metastasis, and evasion of
apoptosis (Greenhough et al. 2009). In contrast, increased production of PGD2 results in
decreased growth of cancer (Park et al. 2007). It has been hypothesized that this is not
through the direct activity of PGD2 but due to either the association of the PGD2 product,
15dPGJ2, with PPARγ or through depletion of PGE2 through increased PGD2 synthesis
(Sertznig et al. 2007, Wang and Dubois 2010).
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The expression of cPLA2 and COX2 has been shown to be positively correlated
in colorectal cancer, likely due to the requirement of free arachidonic acid for
prostaglandin production (Panel et al. 2006). Unsurprisingly, cPLA2 has been shown to
be overexpressed in a number of cancers and associated with cancer development (Hong
et al. 2001, Meyer et al. 2004, Murakami et al. 2011). In breast cancer, cPLA2 activity
correlates with molecular subtype (Caiazza, Harvey, and Thomas 2010). In both
established cell lines and patient tissue, cPLA2 mRNA is significantly elevated in basallike versus luminal-like breast cancer (Caiazza et al. 2011). In agreement with these
observations, 1H nuclear magnetic resonance (NMR) analysis of glycerophosphocholine,
generated through the hydrolysis of phosphatidylcholine by cPLA2, is markedly elevated
in basal-like cancers compared to luminal-like cancers (Moestue et al. 2010). In luminallike breast cancer, it has been shown that estradiol-2 can lead to rapid phosphorylation
and subsequent activation of cPLA2 through an EGFR mediated mechanism (Caiazza,
Harvey, and Thomas 2010). Furthermore, a correlation between cPLA2 mRNA and
EGFR mRNA has been shown in both basal-like and luminal-like breast cancers (Caiazza
et al. 2011). It has been suggested that cPLA2 activation through EGFR is a possible
mechanism for the development of resistance to estrogen receptor therapy. In support of
this claim, it has been shown that luminal-like patients with higher levels of cPLA2 have
a significantly lower rate of overall survival (Caiazza et al. 2011). As a result, cPLA2 is
emerging as a useful biomarker for the differentiation of breast cancer subtypes and a
predictor for the likelihood of resistance generation to estrogen receptor therapy.
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1.4

Molecular Imaging and Cancer
There are a number of platforms for cancer imaging currently in clinical and

preclinical use, including X-ray computed tomography (CT), ultrasound, magnetic
resonance imaging/spectroscopy (MRI/MRS), positron emission tomography (PET), and
fluorescence. Depending on the technique employed, anatomical, physiological, and/or
molecular information about cancer can be obtained. Imaging may be performed with the
use of exogenous contrast agents or may rely on the distinction of endogenous features
visualized through energy/tissue interfaces. Molecular imaging of cancer offers the
potential to provide phenotypic and genotypic information in addition to anatomical
tumor location. Real-time knowledge of the molecular characteristics of tumors allows
for the determination, monitoring, and possible alteration of treatment protocols
(Weissleder 2006). In addition, tools that can assess cancer signatures in in vivo models
can fuel anticancer drug design and evaluation (Willmann et al. 2008).
CT, ultrasound, and MRI are all widely used in clinical practice. Traditionally,
these modalities have been used for anatomical imaging. Although this remains their
primary use, research in the use of these techniques for molecular imaging has been of
increased interest. Smart or targeted contrast agents have been utilized in these
modalities to image molecular characteristics unique to cancer. As an example, gold
nanoparticles conjugated to a prostate specific membrane antigen (PMSA) RNA aptamer
were used to image PMSA expressing prostate cancer using CT (Popovtzer et al. 2008).
Αvβ3 integrin targeted microbubbles have been used to image tumor associated
angiogenesis using ultrasound (Willmann et al. 2010). Finally, MRI contrast agents
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targeted towards the folate receptor have been used for the molecular imaging of ovarian
cancer (Konda et al. 2001). Numerous other contrast agents have been targeted towards
cancer-associated markers using these techniques.
MRS has been investigated in combination with MRI for molecular imaging of
cancer. By defining a cancerous region of interest (ROI) with MRI, MRS has been
successfully used to map the spatial distribution of many metabolites including total
choline, which is elevated in cancer, providing the ability to evaluate cancer metabolism
along with giving insight into intertumoral spatial heterogeneity (Horska and Barker
2010). In a separate study, the level of MR visible mobile lipids within tumors was
shown to correlate with apoptosis and provided a measure of the efficacy of anti-cancer
therapy (Liimatainen et al. 2008). Though MRS is a promising tool for providing
molecular and functional information, low sensitivity remains problematic.
Positron emission tomography (PET) was one of the first imaging techniques to
provide solely functional information on cancer. By exploiting the Warburg effect,
radiolabeled fluorodeoxyglucose (18F-FDG) is taken up to a higher degree in
metabolically active cancers. Coupled with CT, this technique has become a standard
clinical tool for the evaluation of solid tumors and the measurement of tumor response to
therapy (Kelloff et al. 2005).
1.5

Optical Imaging
Optical imaging has yet to see widespread adoption in clinical practice but has

become the most widely used imaging technique in research settings. This is possibly
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due to the versatility of optical imaging agents, which can be engineered to provide
highly specific information on various molecular targets (Weissleder and Pittet 2008).
Optical imaging agents rely on the emission of photons within the visible-NIR range,
either through bioluminescence or fluorescence to obtain molecular information.
Bioluminescence imaging is most commonly used in systems engineered to
express the luciferase protein. When the luciferase substrate, luciferin, is added to the
system, light is produced through an ATP and O2 dependent reaction (Wilson and
Hastings 1998). This reporter system has been used to measure the transcriptional
regulation of various oncogenes, the activation of apoptosis, and the response of cancer
associated genes to therapy (Gross and Piwnica-Worms 2005). Bioluminescence has been
used as a tool for cellular analysis and an in vivo research tool. In mice, cancer cells
expressing luciferase are often used to
monitor tumor growth with time and the
effect of anti-cancer therapy on tumor size
(Lim, Modi, and Kim 2009).
Fluorescence imaging relies on the
detection of endogenous or exogenous
Figure 1.3. The Near Infrared (NIR) window.
The NIR window (670-900 nm) is a region of the
electromagnetic spectrum with minimal absorption
from hemoglobin and water. Fluorophores which
emit within the NIR window have greater tissue
penetration and detection sensitivity. Reprinted by
permission from Macmillan Publishers Ltd: Nature
Biotechnology (Weissleder 2001), copyright (2001).

fluorophores following the input of
excitation energy. Similarly to luciferase,
fluorescent proteins have seen widespread
research use for their ability to serve as
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genetic reporters (Gross and Piwnica-Worms 2005). Green fluorescent protein (GFP),
which was the subject of the 2008 Nobel Prize in chemistry, was the first fluorescent
protein to be designed. Due to the wavelength of GFP, applications to in vivo imaging
are limited due to the poor tissue penetration and scattering of green light. For in vivo
imaging, red shifted fluorescence between 650-900 nm is ideal (Weissleder 2001). This
NIR window has low absorbance from hemoglobin and water allowing for maximum
penetration of light and increased signal detection (Figure 1.3). In addition, light
scattering, the process of absorption and re-emission of light in the non-forward direction
of travel, can result in signal loss (Ntziachristos 2010). Similar to issues with light
absorption, scattering is decreased at higher wavelengths, making the NIR window ideal
for biological imaging. The development of longer wavelength fluorescence proteins
such as red fluorescent protein (RFP), near infrared fluorescent protein (NIRFP), and
Infrared Protein (IFP) have since expanded their in vivo capabilities (Shcherbakova and
Verkhusha 2013, Shu et al. 2009).
Unlike genetic reporters, small molecule fluorophores are exogenous agents,
which can be used to obtain functional information when added to cells or in vivo
systems. Reporter fluorophores can be categorized into three groups based on their
mechanism of action: Nonspecific distributing agents, targeted agents, and activatable
agents (Weissleder 2001). Nonspecific distributing agents are free fluorophores, which
distribute through tissue based on blood flow and perfusion. They are not targeted and
therefore are most useful for the measurement of vascular perturbations. Three
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fluorophores within this category, indocyanine green, fluorescein, and methylene blue
have seen clinical adoption and are FDA approved for the evaluation of disease.
Indocyanine green (ICG) is a tricarbocyanine dye with fluorescence in the NIR
region. ICG has no functional groups, limiting its potential for conjugation to targeting
moieties, however it is highly useful in the measurement of vascular blood flow
(Marshall et al. 2010). ICG is clinically approved for determining cardiac output, hepatic
function and liver blood flow and for ophthalmic angiography (Nguyen and Tsien 2013).
Fluorescein is a clinically approved dye with fluorescence emission at 520 nm.
Because of this lower wavelength, fluorescein has poor tissue penetration, but can be
used successfully for measuring vascular flow in the eye. Fluorescein is clinically
approved for diagnostic angiography or angioscopy of the retina and iris vasculature
(Nguyen and Tsien 2013).
One method of improving fluorescence contrast is to conjugate fluorophores to
targeting ligands. Similar to molecular imaging techniques discussed for CT, ultrasound,
and MRI, this allows for selective accumulation of signal in the vicinity of the target.
Targeting fluorophores results in an improved signal to background as a function of time
as non-bound fluorophore clears from circulation. NIR targeted dyes have been used to
image cancer signatures including folate receptor, EGFR, and HER2/Neu (Moon et al.
2003, Ke et al. 2003, Terwisscha van Scheltinga et al. 2011). In addition, probes have
been designed targeted towards markers of apoptosis such as phosphatidylserine exposure
on the outer leaflet of the cell membrane (Zhang and Zhao 2013).
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Though problems faced in absorption and scattering of light can be mitigated by
imaging within the NIR window, issues with detection sensitivity remain. In mouse
models, fluorescence from alfalfa-containing chow can lead to high background signal in
the digestive tract. This fluorescence can be significantly decreased by feeding mice
purified chow with inherently low fluorescence (Inoue et al. 2008). The combination of
this low fluorescence diet and NIR fluorescence has made optical imaging in mice a
powerful research tool for the evaluation of cancer. Despite this, translation of these
techniques to humans remains challenging due to larger tissue depths. Certain tissue is
more amenable to optical imaging then others and must be taken into consideration when
developing fluorescent imaging agents. Breast tissue, due to its fatty composition and
compressibility has been shown to allow up to 10 cm of penetration by NIR light
(Weissleder 2001).
1.6

Activatable Fluorescence
Activatable fluorescence offers a number of advantages to both free and targeted

fluorophores. Targeted molecular imaging agents provide a measurement of target
expression; however activatable agents can provide a measure of not only protein
expression, but enzymatic activity as well. In addition, the signal to noise of an
activatable agent is not solely dependent on the rate of clearance but also upon the
activity of the target. Finally, in addition to providing a high degree of functional
information, a single enzyme can cleave multiple substrate molecules, allowing for the
amplification of a signal through increased accumulation of fluorescent product,
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decreasing background signal, and thus increasing detection sensitivity (Rao, DragulescuAndrasi, and Yao 2007).
A commonly used research method of fluorescence activation is Föster (or
Fluorescence) Resonance Energy Transfer (FRET). FRET imaging exploits non radiative
energy transfer between a donor fluorophore and an acceptor chromophore (which may
also be fluorescent) in close spatial proximity (Jares-Erijman and Jovin 2003). When two
fluorophores are used, energy is transferred from a lower wavelength emission to a higher
wavelength emission by intermediate absorption by the longer wavelength fluorophore.
The intensity of the higher wavelength emission can be used as a measure for the degree
of spatial interaction between the two fluorophores, since the strength of the interaction
depends on the inverse sixth power of the interfluorophore distance. FRET based
technologies have been utilized extensively in research and have been used to image
numerous biological processes including RAS signaling and calcium signaling related to
cancer (Murakoshi et al. 2004, Mochizuki et al. 2001).
Incorporation of non-fluorescent chromophores in FRET based imaging is
referred to as ‘dark quenching’ (Jares-Erijman and Jovin 2003). Because fluorescence is
dissipated through vibrational relaxation of the dark quencher, the complex remains dark
when in close proximity, and only becomes fluorescent upon separation of the
fluorophore from the dark quencher. One of the earliest activatable probes based on this
design was developed for the detection of nucleic acids (Tyagi and Kramer 1996). This
probe consisted of single strand DNA with a target strand lying in the middle of two
complementary arms which annealed in solution. One arm was esterified to a
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fluorophore, and the other to a complimentary dark quencher. When annealed, the
complex was non-fluorescent, however following hybridization of the middle target
strand to a homologous strand of DNA, the fluorophore and quencher were separated
resulting in fluorescence emission.
A third mechanism of quenching useful for the development of activatable
fluorophores is contact quenching. When fluorophores are within a tight spatial
proximity, they can undergo stacking and result in loss of fluorescence. Recently, this
quenching mechanism has been exploited for imaging of secreted phospholipase A2
using the phospholipid conjugated fluorophore, 1-palmitoyl-2-(6-((7-nitro-2-1,3benzoxadiazol-4-yl)amino)hexanoyl)-sn-glycero-3-phosphocholine (NBD-PC). By
incorporating NBD-PC into micelles at a high mole fraction, 90% quenching of
fluorescence was achievable. The addition of sPLA2 resulted in disruption of the
micelles and a restoration of fluorescence (Gao et al. 2015).
Several protease activatable fluorophores have been developed using both dark
quenching and contact quenching. One of the earliest designed involved a graft
copolymer consisting of poly-L-lysine incorporating the fluorophore, Cy 5.5, quenched
through contact quenching. Cleavage of the polypeptide from lysosomal cysteine/serine
proteases in tumors allowed for activation of fluorescence and imaging of cancer
(Weissleder et al. 1999). Expanding from this design, a matrix metalloprotease (MMP)
sensitive probe was developed conjugated to Cy 5.5 and specific to MMP-2 (Bremer,
Tung, and Weissleder 2001). Probes similar to these are commercially available under
the trade names ProSense and MMPSense and have been used for research on the
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detection of colorectal cancer, pancreatic cancer, and the investigation of breast cancer
progression (von Burstin et al. 2008, Clapper et al. 2011, Baeten et al. 2009).
Phospholipase specific probes have also been developed using dark quenching.
By placing a fluorophore at the sn-2 position of a phospholipid and replacing the head
group for a quencher, PLC selective activatable probes were generated and shown to be
capable of imaging PLC in tumors (Mawn et al. 2011). Similar probes were developed
for specificity towards PLA2 by incorporating a 12-carbon spacer between the
fluorophore and ester linkage at the sn-2 position (Popov et al. 2010). In designing a
cPLA2 activatable fluorophore, arachidonic acid at the sn-2 position is necessary since
cPLA2 is the only phospholipase with absolute specificity for arachidonic acid at this
position (Gijon and Leslie 1999). Furthermore, crystallographic analysis of
cPLA2 identifies a small pocket where the phospholipid head group lies during lipolysis
(Dessen et al. 1999). The presence of a large quencher at this position would most likely
decrease activity due to steric hindrance.
An alternate method for generating activatable fluorescence is to use chemical
caging of fluorophores (Ellis-Davies 2007). This technique avoids the need for a bulky
quencher, which can often interfere with enzymatic activity. In addition, this technique
does not rely on spatial distances for quenching and therefore a higher percentage of
quenched fluorescence can be achieved. Chemical caging involves the esterification or
amidification of resonant active hydroxyls or amides resulting in altered fluorescent
properties.
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Such probes have been designed with photo-labile groups, which become actively
fluorescent only after light is introduced into the system (Warther et al. 2010). βgalactosidase sensitive probes have also been designed using this technique through
conjugation with beta galactose (Tung et al. 2004, Kamiya et al. 2007). Sulfatase
sensitive probes have been developed through conjugation with sulfate (Beatty et al.
2013). Similarly activatable probes targeted towards reactive oxygen species through
conjugation with aryloxyphenols have been developed (Setsukinai et al. 2003). Finally,
γ-glutamyl hydroxymethyl rhodamine green was developed and found to specifically
activate in the presence of γ-glutamyltranspeptidase, which is overexpressed in various
cancers (Urano et al. 2011).
A phospholipase activatable fluorophore was developed previously using caged
fluorescence (Huang et al. 1994). In this design, arachidonic acid was conjugated to 7hydroxycoumarin (7-HC) through esterification of the free hydroxyl. It was shown that
this probe could be activated in the presence of purified cPLA2. Intriguingly, this
activation was shown to occur at an identical rate to that of endogenous substrate
implying that cPLA2 activity does not require an intact phospholipid with a glycerol
backbone and phosphorylated head group.
A major limitation to the design of 7-HC is the fluorescence emission of 7-HC,
which occurs at a 460 nm maximum wavelength. Probes within this region of visible
light have significant absorption in biological tissue due to the presence of hemoglobin
(Weissleder 2001). For in vivo imaging, fluorescence within the NIR region (Figure 1.3)
is ideal for limiting tissue absorption and allowing maximum penetration of light.
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1.7

Near Infrared Fluorescence Guided Surgery
Fluorescence guided surgery is a technique rapidly gaining attention within the

scientific and medical communities. Fluorophores which either accumulate in tumors or
which activate specifically in tumors can provide a guide for surgeons and increase the
efficacy of tumor resection, thereby minimizing the potential for tumor reoccurrence and
metastasis (Nguyen and Tsien 2013). The success of surgical resection is evaluated using
histology by analyzing the surgical margins of the excised tissue (Singletary 2002).
‘Positive margins’, the case where cancer cells lie at the cut edge, have been correlated
with increased probability of recurrence and metastasis (Meric et al. 2003).
Fluorophores, which accumulate in tumors are typically given intravenously and must be
optimized with respect to dose and time in order to allow for systemic clearance thereby
decreasing background and maximizing signal to noise (Nguyen and Tsien 2013).
Activatable fluorophores allow for topical application during surgery, thereby eliminating
the need for systemic administration. This reduces the time necessary to obtain suitable
contrast and reduces the amount of compound that is needed, which can minimize side
effects. In breast cancer specifically there is a great need for improved tumor resection as
the positive surgical margin rates have been shown to range from 5-49% based on the
study performed (Vahrmeijer et al. 2013).
As previously discussed, ICG and fluorescein are both under investigation for
their use as contrast agents in fluorescence guided surgery (Nguyen and Tsien 2013).
Because both are FDA approved, they offer reduced challenges in designing off-label
clinical trials. ICG distributes diffusely and accumulates within tumors through the
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presence of increased tumor vasculature (Marshall et al. 2010). ICG, injected i.v., has
been extensively investigated for its ability to aid the surgical resection of several
carcinomas including skin, gastrointestinal, lung and breast (Schaafsma et al. 2011, Judy
et al. 2015, Keating et al. 2016). Adverse effects of systemic ICG administration have
been observed including anaphylaxis (Hope-Ross et al. 1994). Like ICG, fluorescein also
distributes diffusely. In a study using fluorescein for the guided resection of gliomas,
patients with fluorescein administered i.v. had a higher rate of gross total tumor resection
(Shinoda et al. 2003). In addition patients who underwent gross total tumor resection had
a significantly enhanced survival, giving further evidence for the value of complete tumor
resection during surgery. Unlike ICG, fluorescein does not fluoresce in the NIR.
Therefore, high doses were needed for tumor visualization increasing the risk of offtarget effects, a potential limiting factor in future development.
Efforts to improve fluorescein accumulation in cancer, and thus increase detection
sensitivity, have been carried out through conjugation to folate resulting in targeted
accumulation on the folate receptor, overexpressed in numerous cancers (van Dam et al.
2011). An in human study on the surgical use of folate conjugated fluorescein in ovarian
cancer demonstrated its ability to enhance the detection of tumor deposits versus visual
inspection.
Antibody conjugation has also emerged as a viable means of targeting
fluorophores to cancerous tissue for the aid of surgical resection. In a study investigating
the surgical resection of melanoma, bevacizumab, panitumumab, tocilizumab or nonspecific IgG were conjugated to an NIR fluorophore (IRDye800CW) and injected i.v. in
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mice bearing melanoma tumor xenografts. It was determined that all antibody
conjugated dyes, with the exception of IgG control, were able to discern cancerous from
healthy tissue (Day et al. 2013).
5-aminolevulinic acid (5-ALA) is a precursor for porphyrin synthesis needed for
the generation of hemoglobin. 5-ALA is non-fluorescent, but can be taken up by cancer
cells and converted to fluorescent protoporphyrin IX as part of the synthesis of heme
(Regula et al. 1995). Unlike ICG and fluorescein, 5-ALA is a prodrug and not dependent
to the same degree on disrupted vasculature. 5-ALA is under investigation for
fluorescence guided surgery and has shown promise for its use in the surgical resection of
gliomas. In a phase III clinical study it was shown that the patient group which
underwent 5-ALA guided surgery had a decreased percentage of repeat surgery and an
increased 6-month progression free survival compared to the control cohort not treated
with 5-ALA (Stummer et al. 2006).
The growth of activatable fluorophores can expand the capabilities of
fluorescence guided surgery and decrease the reliance on vasculature fluorophore
retention, which may vary between tumors. In addition, probes are also required that can
identify cancerous tissue at sites distal to the primary tumor which may have more
normalized vasculature and not respond to perfusion based fluorophores. Finally, agents
that are selective to molecular characteristics of cancer can provide functional
information while serving as a guide for resection.
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1.8

Scope of Thesis
This project aims to develop cPLA2 selective activatable red-shifted fluorophores

for use in the exploration of cPLA2 activity in breast cancer and for their use as a contrast
agent for NIR fluorescence guided surgery. Our investigation began with the observation
that 7-HC was hydrolyzed by purified cPLA2 despite the absence of a glycerol backbone
and phosphorylated head group. We therefore first set out to synthesize arachidonic acid
esterified fluorophores, similar in structure to 7-HC, but employing fluorophores shifted
closer to the NIR window. We then evaluated the specificity of the developed probes to
cPLA2 in breast cancer cell lines. Finally, we assessed the activation of cPLA2-sensitive
probes in vivo to gauge their potential as contrast agents for surgical resection.
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Chapter 2: Materials and Methods
2.1

Materials
Solvents for synthesis were purchased through Fisher Scientific. Resorufin,

resorufin sodium salt, naphthofluorescein, palmitoyl chloride, porcine pancreatic
phospholipase A2, arachidonyl trifluoromethyl ketone, bromoenol lactone, ionomycin,
and H2O2 30% (w/w) were purchased from Sigma-Aldrich. 7-Hydroxy-9H-(1,3-dichloro9,9-dimethylacridin-2- one (DDAO), arachidonoyl chloride, and LY311727 were
purchased from Santa Cruz Biotechnology. 7-HC was purchased from Cayman Chemical.
Syto 9 was purchased from Life Technologies. HOESCHT 333258 was generously
provided by the Cellular and Molecular Imaging Core Facility (CMIC) at the Norwegian
University of Science and Technology (NTNU). Egg phosphatidylcholine was purchased
from Avanti Polar Lipids. AVX-235 was provided by Dr. Berit Johansen from Avexxin
Pharmaceuticals (Trondheim Norway). MDA-MB-231, SKBR3, and MCF-7 cell lines
were purchased from the American Type Culture Collection (ATCC). 4175-Luc+ cell
line, a lung metastatic derivative of the MDA-MB-231 cell line was generously provided
by Dr. Andy Minn (Minn et al. 2005). Human cPLA2 rabbit monoclonal antibody and
human β-tubulin rabbit monoclonal antibody were purchased through Cell Signaling
Technology. IRDye® 800 conjugated goat anti-rabbit IgG was purchased through LICOR Biosciences. Athymic NCR nu/nu 01B7 female mice were purchased through
Charles River, Production. cPLA2 CRISPR/Cas9 KO Plasmid, control CRISPR/Cas9
plasmid, UltraCruz® transfection reagent and plasmid transfection media were purchased
through Santa Cruz Biotechnology.
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2.2

Flash Column Chromatography
A 1000 mL stopcock separation column was dried overnight under air flow.

Approximately 1/3 of the column was loaded with silica gel suspended in hexanes. The
walls of the column were rinsed evenly with hexanes to transfer all silica gel to the
bottom. The column was packed with a hexanes mobile phase under pressurized air. A
small layer of sand was added onto the silica gel to protect from physical perturbation.
The sample was dissolved in the smallest possible volume of hexanes and separated
under pressurized air according the procedures described.
2.3

1

H NMR Spectroscopy

Samples were dried through rotary evaporation and lyophilized overnight to
remove residual solvents. Samples were dissolved in the appropriate deuterated solvent
based on solubility and spectra obtained on a 360 MHz Bruker Avance DMX
spectrometer with gradient capabilities running the Topspin software package.
Shimming was adjusted through optimization of the lock signal by adjustment of x, y,
and z gradients without spinning, then adjustment of z and z2 gradients with spinning at
20 Hz. Spectra were acquired using a zg30 pulse sequence (NS= 16, SW = 20.6 ppm).
The spectra were analyzed with MestReNova software. First and second order phases
were adjusted relative to the highest intensity peak and baseline was adjusted using a
Whitaker baseline correction. Signals were referenced to the solvent peak.
2.4

Mass Spectrometry
Matrix-assisted laser desorption / ionization time of flight (MALDI-TOF) was

performed on a Bruker MALDI-TOF. Samples were prepared in saturated solutions of
either 2-(4′-hydroxybenzeneazo)benzoic acid or α- cyano-4-hydroxycinnamic acid as a
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50:50 mixture (acetonitrile/ H2O) with 0.1% trifluoroacetic acid. 1 µL of each sample
was placed on an MTP AnchorChip TM 600/384 TF MALDI target (BrukerDaltonik).
The mixture was dried at room temperature to allow for matrix crystallization. Spectra
were generated using an Autoflex III smartbeam 1 MALDI-TOF-MS mass spectrometer
(BrukerDaltonik) operating in the linear and reflectron positive ion mode. A smartbeam
laser (200 Hz) was used to irradiate matrix and generate ions. Electrospray ionization
(ESI) mass spectrometry was performed with a Single Quadrapole (SQ) Detector
(Waters) coupled with Ultra Pure Liquid Chromatography (Acquity). Samples were
dissolved in ethanol and passed through a gradient (80 - 20%) of acetonitrile in water.
Results were analyzed using MestReNova for the presence of ions with predicted product
mass.
2.5

Liposomal Preparation
Probe and egg phosphatidylcholine were mixed together in a 25 mL round bottom

flask in chloroform at a mole fraction of 0.05-0.1. The solvent was removed under a
slow stream of nitrogen gas. The resulting lipid cake was resuspended in aqueous buffer
followed by sonication in a 4 °C water bath sonicator until an optically clear solution was
obtained, typically 10-15 minutes. Buffer was added to result in a concentration of 100
µM probe for in vitro and 400 µM probe for in vivo analysis. Liposomes were used
immediately following formation.
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2.6

In Vitro sPLA2 Assay
In a 96 well plate, 80 μL of 50 mM Tris (pH 7.4) with 1.1 mM CaCl2 was mixed

with 0−100 units of sPLA2 Group IB (Sigma) in the presence or absence of 100 μM
LY311727 (Santa Cruz Biotech) in DMSO resulting in a total volume of 90 μL per well.
To initiate the reaction, 10 μL of liposomes containing activatable probe was added to
each well, and fluorescence was measured as a function of time on a Spectra Max M5
fluorescent plate reader (top read; ex/em, 600/660 nm for DDAO, 595/660 nm for
naphthofluorescein, and 572/585 nm for resorufin).

2.7

Cell Culture
All cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM)

supplemented with 10% fetal bovine serum (HyClone Laboratories), 1% L-glutamine
(Mediatech), and 1% penicillin−streptomycin (Mediatech). 4175-Luc+ cells were
additionally maintained with 5 µg/mL blasticidin (Invitrogen). Frozen cells (1-2 x 106
cells per vial) were brought up through a rapid thaw at 37ºC and immediately placed in
10 mL of 37 °C media. DMSO containing freezing media was removed through
centrifugation (1000 rpm, 4 °C, 4 min) and cell pellet was resuspended in 8 mL of media
at 37 °C. Cells were expanded and maintained at 37 °C, 5% CO2, in a humidified
environment. Cells were tested immediately upon receipt and bi-annually thereafter for
mycoplasma.
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Cells were passaged routinely through washing 2x with 4 °C Phosphate Buffered
Saline (PBS) followed by detachment from the tissue culture flask through addition of
Trypsin-EDTA (0.25%) (Thermo Fisher Scientific). Following detachment, the protease
was neutralized through addition of fresh 37 °C media with serum. Cells were split at a
1:10 ratio, and used for up to 20 passages before being discarded. Cells were counted on
a Neubauer hemocytometer following centrifugation at 1000 rpm, resuspention in PBS
and dilution (1:1) with Trypan Blue to stain for non-viable cells.
2.8

Cellular Fluorescence Activation Assay
Cells were seeded at 1.5-3.5 x 104 cells in a 96-well black-wall, clear-bottom plate

24 hours prior to experiment. The medium was aspirated, and cells were washed 1× in
0.1 mL of PBS (4°C, without Ca2+ and Mg2+), and 90 μL of phenol red free DMEM
containing drug treatments or vehicle control was added to each well. For phospholipase
inhibition experiments, 10 µM inhibitor was incubated with cells for 4 hours (2.5 hours
for AVX-235). Assays were initiated by adding 10µL of liposomes containing DDAO
fluorescent probes to the wells. Fluorescence was monitored as a function of time on a
Spectra Max M5 fluorescent plate reader at 37°C (bottom read, ex/em 600/660 nm). For
AVX-235 inhibition and cellular comparison studies, fluorescence was monitored as a
function of time on a LI-COR Odyssey® CLx Imaging System (700 nm channel, ex/em:
685/720).

32

2.9

Fluorescence Microscopy

Wide Field Fluorescence Microscopy
4175-Luc+ cells were seeded at 2.5 × 105 cells/mL in 0.5 mL and cultured
overnight in a 24-well plate. The media was aspirated, and the cells were washed 2× in
PBS. Phenol red free DMEM (450 μL) with 1 μM Syto 9 (Invitrogen) was added to each
well 3 h prior to analysis. Liposomes were added either 30 minutes or 3 h prior to
analysis. Immediately before analysis, DMEM was aspirated, cells were washed 1× in
PBS, and fresh phenol red free DMEM was added. For live cell time course microscopy,
the probe was added immediately prior to analysis, the plate was loaded into a 5% CO2,
37 °C chamber and allowed to equilibrate for 30 minutes. Wide field fluorescence
microscopy was performed on an EVOS FL Auto Cell Imaging System (Life
Technologies). An LED light cube for Cy5 was used to excite DDAO fluorescence, and a
GFP light cube was used to excite Syto9 fluorescence. Images were acquired at 40×
magnification and analyzed with ImageJ.
Confocal Fluorescence Microscopy
Cells were seeded at 1.5-3.5 x 104 cells in a 96 well black-wall, clear bottom plate
24 hours prior to experiment. The medium was aspirated, and cells were washed 1× in
0.1 mL of PBS (4 °C, without Ca2+ and Mg2+), and 90 μL of phenol red free DMEM
containing drug treatments or vehicle control was added to each well. For phospholipase
inhibition experiments, 10 µM AVX-235 or vehicle control was added and cells were
incubated for 1.5 hours. 10 μL of probe containing liposomes in PBS was added and the
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plate was incubated for 2.5 hours at 37 °C. The medium was removed and 100 μL of
phenol red and FBS free media (37 °C) was added. 1 µL of HOESCHT 333258 nuclear
stain was added. Confocal fluorescence microscopy was performed on a Leica SP8
imaging system and analyzed with Image J.
2.10

In Vivo Mouse Models

Anesthesia
Isoflurane was administered to achieve anesthesia. In a clean induction chamber,
1-5 mice were simultaneously induced with 1 L/min O2 containing 4% isoflurane.
Induction was assessed through loss of movement, slowed rate of breathing, and an
absence to response of a toe pinch. Anesthetized mice were maintained at 1 L/min O2
containing 2% isoflurane.
Euthanization
Mice in a cage without a filtered lid were placed in a clean CO2 chamber and
sealed. CO2 was injected at a fill rate of 10-30% chamber volume displacement per
minute for 10 minutes. Mice were monitored continuously during the procedure and
assessed for lack of movement. Euthanization was confirmed through cervical
dislocation.
Tumor Inoculation
Cells were expanded in T-150 tissue culture flasks to ~80% confluency. Cells
were detached through trypsinization, washed 2x in 4 °C PBS, and adjusted to 2 x 106
cells / 100 µL of PBS. The suspension was diluted 1:1 with 4 °C Matrigel® (Corning)
and placed in a 6-well plate on ice. Prior to injection, cells were resuspended and drawn
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up into a 1 mL syringe with a 27-gauge needle. Air bubbles were removed through
gentle tapping. The syringe was depressed until a stream of cell media was ejected
consistently without air. The area of injection was sterilized with 70% isopropanol. For
tumor xenograft inoculation, the cells were injected subcutaneously in the right or left
lower flank or superior shoulder flank. For orthotopic inoculation, cells were injected
into the mammary fat pad inferior to the lower nipple of the mouse. The mammary fat
pad was located by gently pinching the skin and held in place for inoculation. Following
injection, sterile gauze was used to aid in clotting. Mice were monitored the day
following inoculation and every three days thereafter in order to assess tumor growth and
to evaluate general health.
Probe Injections
For intravenous (i.v.) injection, mice were anesthetized as previously described.
The tail vein was dilated through immersion of the tail in 37 °C water. Prior to injection,
the compound was drawn up into a 1 mL syringe with a 30-gauge needle. Air bubbles
were removed through gentle tapping. The syringe was depressed until a stream of fluid
was ejected consistently without air. The tail was sterilized with 70% isopropanol.
Following application of tension to the tail, the needle was inserted level with the vein.
For intraperitoneal (i.p.) injections, mice were used either with or without
anesthesia. Prior to injection, compound was drawn up into a 1 mL syringe with a 30gauge needle and treated as before. The area of injection was sterilized with 70%
isopropanol. Injection was done in the right or left lower abdominal quadrant in order to
avoid the anterior liver and bladder in the midline.
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2.11

Optical Imaging

IVIS Spectrum
Fluorescence was acquired on a PerkinElmer IVIS Spectrum using a 640 nm
excitation filter and a 680 nm emission filter (Bin: (M)8, FOV: 22.3 cm2, f2, 3s
exposure). For spectral unmixing, two excitation filters in combination with emission
filters were used (570 nm excitation with emission 620-780 nm in 20 nm intervals and
640 nm excitation with emission 680-780 nm in 20 nm intervals). Images were
processed and quantitated in LivingImage 4.4. ROIs were defined with circular shape
tools. Fluorescence is reported, unless otherwise noted, as Average Radiant Efficiency,
measured in photons per second and corrected for the area of the ROI and the light source
efficiency at the acquired sample distance and filter settings ([p/sec/cm2/sr]/[µW/cm2]).
LI-COR Pearl Impulse
Fluorescence was acquired on a LI-COR Pearl Impulse scanner using the 700 nm
fluorescence channel (ex/em: 685/720 nm). Images were processed and quantified in
Image Studio Lite. ROIs were defined by tracing the tissue in white light mode.
Fluorescence is quantified as relative fluorescence units, unless otherwise noted.
2.12

Ex Vivo Tumor Imaging
48 hours after injection of 40 nmol probe, mice were euthanized according to the

previously described protocol. Tumor and organs were resected, washed in PBS, and
weighed. Tissue was placed in a 24 well plate. Fluorescence was acquired (ex/em:
640/680 nm). ROIs were defined and quantified in LivingImage.
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2.13

Ex Vivo Tumor Painting
Untreated mice bearing orthotopic or xenograft tumors were euthanized according

to the previously described protocol and tissue was resected. Tissue was washed in PBS
and sliced evenly using a razor into approximately 1 mm sections, which were weighed.
The sections were placed in DMEM with serum and cultured for two hours at 37 °C, 5%
CO2. The medium was replaced with phenol red and serum free media (37 °C) prior to
the addition of probe. Liposomes (100 µL containing 20 nmol probe at MF 0.05) were
pipetted evenly on top of the tissue. For analysis, the plate was transferred to either the
IVIS Spectrum or LI-COR Pearl Impulse imaging systems. Fluorescence was acquired at
ex/em: 640/680 or 700 nm channel, respectively for each imaging system. Fluorescence
emission was quantified with LivingImage or Image Studio Lite, respectively.
2.14

Protein Immunoblot
Cells were plated in 10 cm dishes at 2.5 × 105 cell/mL in 12 mL of medium 24

hours prior to the experiment. Following washing 2× with 4 °C PBS, cells were scraped
on ice in radioimmunoprecipitation assay buffer containing cOmplete, mini EDTA-free
protease inhibitor cocktail (Roche). Samples were vortexted and subjected to three cycles
of freeze-thaw consisting of rapid freezing in liquid N2 followed by quick thaw at 37 °C
using a dry block heater. Cells were sonicated in a 4 °C water bath sonicator for 5
minutes and placed on ice for 15 minutes. Cell debris following lysis was pelleted by
centrifugation (13,000 rpm for 10 min). The supernatant was removed and protein
concentration was quantified using the bicinchonic acid (BCA) protein assay kit (Pierce).
Samples were adjusted to equal concentrations of protein, diluted 1:1 in Laemmli loading
buffer (5% 2-mercaptoethanol), and heated to 95 °C for 5 minutes. 30 μL of
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approximately 25 μg protein per well was resolved on a 10% SDS-PAGE gel and
transferred to a 0.45 µm pore nitrocellulose membrane (Invitrogen). The membrane was
blocked in Odyssey blocking buffer (PBS) (LI-COR Biosciences) and blotted using
primary antibodies for cPLA2 or β-tubulin (Cell Signaling). The membrane was imaged
through incubation with secondary antibody (goat anti-rabbit) conjugated to IRDye®
800CW (LI-COR) and visualized using the LI-COR Odyssey® CLx Imaging System.
Bands were quantified with Image Studio Lite.
2.15

CRISPR Gene Knockout
4175-Luc+ cells were seeded in 6 well plates at 1.5 x 105 cells in 3 mL of

antibiotic-free DMEM and cultured for 24 hours. 2 µg of plasmid DNA was diluted in
150 µL Plasmid Transfection Media. Diluted plasma DNA was added dropwise to 150
µL of Plasmid Transfection Media containing 10 µL of UltraCruz® Transfection Reagent.
The sample was vortexed and left to sit for 20 minutes at room temperature. Prior to
transfection, cells were replaced with 3 mL of fresh antibiotic-free DMEM. Dropwise,
plasma DNA solution was added to the well with gentle swirling. Cells were incubated
for 72 hours without a media change.
Cells were separated based on GFP expression using Fluorescence-Activated Cell
Sorting (FACS) on a BD FACSJAZZ. A non-transfected control was used to define a
fluorescence cut-off prior to separation. Cells were expanded in T25 flasks and used for
up to 5 passages before being discarded.
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2.15

Statistical Analysis
All data are reported as mean ± standard deviation, unless otherwise noted. Data

are listed as an average of three experimental results (n = 3), unless otherwise noted.
Statistical probability (P) values were calculated using Microsoft Excel utilizing a twotailed Students t-test. P values <0.05 were considered to be statistically significant.
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Chapter 3: Chemical Synthesis
3.1

Introduction
This Chapter describes the synthesis of a series of activatable constructs that

release caged fluorescence when hydrolyzed by phospholipases. A cPLA2-activatable
fluorophore probe had previously been described with caged fluorescence by
esterification of arachidonic acid to the resonant active hydroxyl moiety present in 7hydroxycoumarin (7-HC) (Huang et al. 1994). Though promising, the low wavelength
emission of this fluorophore (460 nm) limits its in vivo capabilities. Fluorophores within
the NIR region of the electromagnetic spectrum (650-900 nm) have minimum absorbance
from hemoglobin and water allowing for maximum penetration of light (Weissleder
2001). Therefore, we aimed to improve the design of 7-HC arachidonate using redshifted fluorophores that emit close to or within the NIR window.
The fluorophores were selected based on several properties that would enhance
detection and increase specificity. The fluorophore must possess a resonant active
hydroxyl that can be esterified to result in masked fluorescence. Furthermore, the
wavelength of emission should lie in the NIR window to allow for maximum tissue
penetration. Finally, the fluorophore size must be small enough to allow cleavage by
cPLA2. Crystallographic analysis of cPLA2 has identified a small pocket where the
phospholipid head group lies during lipolysis, therefore large fluorophores would likely
result in steric hindrance, preventing cPLA2 mediated cleavage (Dessen et al. 1999).
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Based on these considerations, three fluorophores were chosen as potential cPLA2
imaging agents (Table 3.1).
Resorufin (ex/em: 572/585 nm) is a small tricyclic fluorophore with one available
hydroxyl group. Resorufin has been shown to have ablated fluorescence upon
conjugation to a photoremovable protecting group (Theriot and Mitchison 1991).
Naphthofluorescein (ex/em: 595/660 nm) contains two resonant active hydroxyl groups
and has been shown to have reduced fluorescence upon conjugation (Sarpara et al. 1999).
These two hydroxyls are available for esterification, allowing for the synthesis of a
diarachidonate probe. 7-Hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO)
Table 3.1. Fluorophores used for fatty acid conjugation. Resorufin, naphthofluorescein, and DDAO
were conjugated to fatty acid(s) through esterification of their free hydroxyl group(s).
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(ex/em: 600/660 nm) is an ortho-dichlorinated carbon analog of resorufin that results in
redshifted fluorescence. DDAO has also been conjugated to form activatable
fluorophores through conjugation of its hydroxyl group resulting in photoactivatable and
sulfatase activatable probes (Beatty et al. 2013, Warther et al. 2010). In order to
synthesize cPLA2 selective activatable probes, free fluorophore was conjugated to
arachidonic acid. Control probes were synthesized through conjugation with palmitic
acid, not expected to be cleavable by cPLA2.
3.2

Naphthofluorescein Diarachidonate
Naphthofluorescein (0.0775 mmol, 33.5 mg) was dissolved in 30 mL of pyridine

at room temperature. Arachidonoyl chloride (0.31 mmol, 100 mg) was added to the
solution. The flask was flushed with argon and left to stir at room temperature for 24 h.
Pyridine was removed through rotary evaporation, and the resulting solid was dissolved
in hexanes and filtered through a porous cotton plug to remove pyridinium salts. The
solution was purified with flash column chromatography (silica gel, under N2) in 25 mL
gradients beginning with ethyl acetate/dichloromethane (DCM) (2:8, v/v), followed by
ethyl acetate/DCM (7:3, v/v), ethyl acetate (pure), and methanol/ethyl acetate (3:7, v/v).
The product was isolated as a dark solid (76.4 mg, 98% yield). 1H NMR (360 MHz,
CDCl3, δ ppm) 8.51 (d, 2H, J = 9.0 Hz, -CH- (Ar)) 7.97 (m, 1H, -CH- (Ar)) 7.55 (m, 2H,
-CH- (Ar)) 7.22 (dd, 4H, J = 9.0, 2.63 Hz, -CH- (Ar)), 7.05 (d, 3H, J = 2.4 Hz, -CH(Ar)), 6.60 (d, 2H, J = 8.8 Hz, -CH- (Ar)) 5.25 (m, 16H, -CH=), 2.70 (m, 12H, =CH-CH2CH=), 2.20 (t, 4H, J = 8.0 Hz, -CH2C(O)), 1.97 (m, 8H, -CH2-CH2-CH2C(O)), 1.58
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(quintet, 4H, J = 7.2 Hz, Bu-CH2-CH=), 1.19 (m, 12H, CH3-CH2-CH2-CH2-), 0.77 (t, 6H,
J = 6.7 Hz, CH3-). EI-MS (m/z): 1004.51 (M)+.
3.3

Resorufin Arachidonate

Resorufin (0.0775 mmol, 16.5 mg) was dissolved in 50 mL of pyridine and slightly
cooled with liquid N2. Resorufin was not completely soluble in solution. Arachidonoyl
chloride (0.31 mmol, 100 mg) was added to the solution. The flask was flushed with
argon and left to stir at room temperature for 24 h. Following the reaction, the solution
was clear with no solids present. Pyridine was removed through rotary evaporation, and
the solid was dissolved in hexanes/DCM (1:1, v/v) and filtered through a porous cotton
plug to remove pyridinium salts. The solution was purified with flash column
chromatography (silica gel, under N2) in 25 mL gradients beginning with hexanes/DCM
(1:1, v/v), followed by hexanes/DCM (9:1, 8:2, 7:3, 6:4, 1:1, 3:7, 1:9, v/v), DCM (pure),
and DCM/ethyl acetate (19:1, v/v). The product was isolated as a yellow solid (7.7 mg,
19.9% yield). 1H NMR (360 MHz, CDCl3, δ ppm) 7.80 (d, 1H, J = 8.7 Hz, -CH- (Ar)),
7.44 (d, 1H, J = 7.4 Hz, -CH- (Ar)), 7.15 (d, 1H, J = 2.2 Hz, -CH- (Ar)) 7.12 (dd, 1H, J =
8.6, 2.5 Hz, -CH- (Ar)), 6.86 (dd, 1H, J = 9.8, 2.0 Hz, -CH- (Ar)), 6.33 (d, 1H, 2.0 Hz,
-CH- (Ar)), 5.38 (m, 8H, -CH=), 2.83 (m, 6H, =CH-CH2-CH=), 2.62 (t, 1H, J = 7.5 Hz,
pro-RS-stereogenic -CHHC(O)) 2.37 (t, 1H, J = 7.5 Hz, pro-RS-stereogenic -CHHC(O)),
2.23 (q, 2H, J = 7.2 Hz, -CH2-CH2-CH2C(O)) 2.14 (q, 2H, J = 7.2 Hz, Bu-CH2-CH=),
1.86 (quintet, 1H, J = 7.5 Hz, pro-RS-stereogenic -CH2-CHH-CH2C(O)) 1.73 (quintet,
1H, J = 7.5 Hz, pro-RS-stereogenic -CH2-CHH-CH2C(O)) 1.30 (m, 6H, CH3-CH2-CH2CH2-), 0.89 (t, 3H, J = 6.9 Hz, CH3-). EI-MS (m/z): 500.45 (M + 1)+.
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3.4

DDAO Arachidonate

DDAO (0.0325 mmol, 10 mg) was dissolved in 50 mL of pyridine. Arachidonoyl
chloride (0.065 mmol, 27 μL) was added to the solution, and the reaction was carried out
as described above. The solid product was dissolved in hexanes/DCM (1:1, v/v), filtered,
and purified with flash column chromatography using 25 mL gradients of hexanes/ DCM
(3:7, 2:8,1:9, v/v), DCM (pure), and DCM/ethyl acetate (19:1, 17:3, 7:3, 4:6, and 2:8,
v/v). The product was isolated as a yellow solid (12.9 mg, 65% yield). 1H NMR (360
MHz, CDCl3, δ ppm) 7.64 (d, 1H, J = 8.6 Hz, -CH- (Ar)), 7.62 (s, 1H, -CH- (Ar)), 7.21
(d, 1H, J = 2.4 Hz, -CH- (Ar)), 7.11 (dd, 1H, J = 8.6, 2.4 Hz, -CH- (Ar)), 5.37 (m, 8H, CH=), 2.81 (m, 6H, =CH-CH2-CH=), 2.59 (t, 2H, J = 7.5 Hz, -CH2C(O)), 2.21 (q, 2H, J =
7.2 Hz, -CH2-CH2-CH2C(O)), 2.03 (q, 2H, J = 6.8 Hz, Bu-CH2-CH=), 1.86 (s, 6H,
C(CH3)2), 1.27 (m, 8H, CH3-CH2-CH2-CH2- and -CH2-CH2C(O), 0.87 (t, 3H, J = 7.2 Hz,
-CH2-CH3). MALDI-TOF-MS (m/z): 593.94 (M)+.
3.5

DDAO Palmitate
DDAO (0.0325 mmol, 10 mg) was dissolved in 50 mL of pyridine. Palmitoyl

chloride (0.065 mmol, 20 μL) was added to the solution. The reaction proceeded as
described above, and the resulting solid was dissolved in hexanes/DCM (1:1, v/v),
filtered, and purified with flash column chromatography using 25 mL gradients of DCM
(pure) and DCM/ethyl acetate (19:1, 9:1, 8:2, and 1:1, v/v). The product was isolated as a
yellow solid (5.9 mg, 33% yield). 1H NMR (360 MHz, CDCl3, δ ppm) 7.65 (d, 1H, J =
8.5 Hz, -CH- (Ar)), 7.62 (s, 1H, -CH- (Ar)), 7.21 (d, 1H, J = 2.4 Hz, -CH- (Ar)), 7.11 (dd,
1H, J = 8.6, 2.4 Hz, -CH- (Ar)), 2.57 (t, 2H, J = 7.6 Hz, -CH2C(O)), 1.86 (s, 6H,
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C(CH3)2), 1.75 (quintet, 2H, J = 7.5 Hz, -CH2-CH2C(O)), 1.24 (m, 24H, CH3-CH2-CH2CH2-CH2-CH2-CH2-), 0.86 (t, 3H, J = 6.9 Hz, -CH2-CH3). MALDI-TOF-MS (m/z):
567.24 (M + 1 + Na)+.
3.6

Resorufin Palmitate
Resorufin sodium salt (0.0774 mmol, 18.2 mg) was dissolved in 80 mL of

pyridine and slightly cooled with liquid N2. Palmitoyl chloride (0.31 mmol, 95 μL) was
added to the solution. The reaction proceeded as described above, and the resulting solid
was dissolved in hexanes, filtered, and purified with flash column chromatography using
25 mL gradients of hexanes/DCM (9:1, 8:2, 6:4, 2:8, v/v), DCM (pure), DCM/ethyl
acetate (9:1, v/v), and ethyl acetate (pure). The product was isolated as a yellow solid (5.0
mg, 14.3%). 1H NMR (360 MHz, CDCl3, δ ppm) 7.80 (d, 1H, J = 8.8 Hz, -CH- (Ar)),
7.43 (d, 1H, J = 10.1 Hz, -CH- (Ar)), 7.15 (d, 1H, J = 2.2 Hz, -CH- (Ar)), 7.12 (dd, 1H, J
= 8.6, 2.5 Hz, -CH- (Ar)), 6.86 (dd, 1H, J = 9.8, 2.0 Hz, -CH- (Ar)), 6.33 (d, 1H, J = 1.8
Hz, -CH- (Ar)), 2.60 (t, 2H, J = 7.6 Hz, -CH2C(O)), 1.77 (quintet, 2H, J = 7.7 Hz, -CH2CH2C(O), 1.26 (m, 24H, CH3-CH2-CH2-CH2-CH2-CH2-CH2-), 0.88 (t, 3H, J = 7.0 Hz,
CH3-). EI-MS (m/z): 452.21 (M + 1)+.
3.7

Results
For all probes, free fluorophore was conjugated to a fatty acyl chloride through a

one-step reaction in pyridine (Figure 3.1). Free fluorophore in pyridine existed as a dark
red solution. Following conjugation to a fatty acid, a change in solution color to yellow
was observed (Figure 3.2). This color change allowed for the visual monitoring of
reaction progress. Color change occurred rapidly (within seconds) when a sufficient
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amount of excess fatty acyl chloride was added to the stirring solution. The molar
equivalents of fatty acyl chloride required to achieve a rapid color change varied for each
given reaction. Naphthofluorescein diarachidonate, resorufin arachidonate, and resorufin
palmitate required 4 equivalents of fatty acyl chloride. DDAO arachidonate and DDAO

Figure 3.1. Scheme for probe synthesis. Free fluorophore was coupled with a fatty acyl chloride
through a one-step reaction in pyridine. Arachidonoyl chloride was used to generate cPLA2 selective
fluorophores. Palmitoyl chloride was used to generate control probes.
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palmitate required 2 equivalents of
fatty acyl chloride.
Column chromatography was
monitored visually with product
appearing as a colored band ranging
from yellow to orange for resorufin
Figure 3.2. Naphthofluorescein palmitate reaction
progress.
A)
Naphthofluorescein dissolved in
pyridine resulted in a dark red solution. B) Addition
of palmitoyl chloride resulted in a change to light
yellow indicating successful conjugation.

and DDAO (Figure 3.3A).
Napthofluorescein diarachidonate
appeared as a dark purple band. In

addition, excitation with U.V. light (ex 312 nm) resulted in fluorescence of the product,
which could be used to monitor the product’s mobility on a silica gel column when
visualized in a darkened room using a U.V. lamp (Figure 3.3B). For all probes, the
product was eluted in early fractions of hexanes / ethyl acetate with slight variations
between syntheses.
Naphthofluorescein displays a maximum absorbance peak at 600 nm. This
absorbance was lost in naphthofluorescein diarachidonate. Addition of 200 µL 1M
NaOH to naphthofluorescein diarachidonate in egg phosphatidylcholine liposomes (MF
0.1) to induce hydrolysis of the ester bond resulted in rapid (<1 min) restoration of the
600 nm absorbance peak at room temperature. Excitation at this wavelength resulted in
fluorescence generation with a maximum of 660 nm. The potential for quenching of
naphthofluorescein diarachidonate was determined by measuring the difference in
fluorescence (ex 600, em 660) of the ionized fluorophore at pH 9 (fluorescent) versus the
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protonated fluorophore at pH 3 (non fluorescent). This change to acidic pH reduced
naphthofluorescein diarachidonate fluorescence by 99.4%.
Conjugation of resorufin to both arachidonic acid and palmitic acid resulted in a
shift of the 572 nm resorufin absorbance peak to 450 nm. Addition of NaOH to induce
hydrolysis of the ester bond resulted in a restoration of the 572 nm peak and a loss of the
450 nm peak. Excitation of resorufin at this wavelength resulted in fluorescence
generation with a maximum of 585 nm. The potential percentage for quenching was
determined by analyzing the difference in
fluorescence (ex 600, em 660) of the
ionized fluorophore at pH 9 versus the
protonated fluorophore at pH 3. This was
determined to be 99.8%.
DDAO contains a broad absorbance
peak between 600 and 650 nm. Similar to
what was observed for resorufin,
conjugation to either arachidonic acid or
palmitic acid resulted in a shift in
absorbance resulting in a broad peak
between 400 and 450 nm. In order to
demonstrate the mechanism of activation
for this compound, 100 Units of secreted
phospholipase A2 (Group IB) was added to

Figure 3.3. Flash column chromatography of
DDAO arachidonate. A) Product can be seen as
a yellow band migrating in the center of the
column. B) Under U.V. light (ex 360 nm) the
product fluoresces, aiding in separation from nonfluorescent compounds.
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Figure 3.4. Mechanism of activation shown for DDAO arachidonate. Absorbance in the esterified
quenched state is shown in solid blue. Absorbance in the unesterified state is shown in red. Cleavage of
the esterified probe (10 µM) generates absorbance at 600-650 nm allowing for fluorescence (dotted red
line) at 660 nm.

egg phosphatidylcholine liposomes containing DDAO arachidonate (MF 0.1) and the
change in absorbance and fluorescence spectra was recorded after 4 hours of incubation
at 37°C in 50 mM Tris supplemented with 1.1 mM CaCl2. It was observed that following
incubation, a restoration of the 600-650 absorbance peak occurred which was
accompanied by a restoration of fluorescence when excited at 600 nm (Figure 3.4).
Determination of the theoretical quenching was performed through comparison of the
fluorescence (ex 600, em 660) of the ionized fluorophore at pH 9 versus the protonated
fluorophore at pH 3 and resulted in a 98.6% quenching of fluorescence.

49

3.8

Discussion
This Chapter describes the synthesis of 5 caged fluorophores which were

produced in high yield using a one-step esterification in pyridine. It was found that
naphthofluorescein and resorufin required 4 equivalents of fatty acyl chloride to drive this
reaction and achieve a color change. DDAO required only 2 equivalents of fatty acyl
chloride for both arachidonate and palmitate probes. In addition, both arachidonate and
palmitate reaction yields were higher for DDAO conjugation versus resorufin
conjugation. This difference in reactant concentrations did not appear to correlate with
reaction yield as naphthofluorescein diarachidonate had the highest yield (98 %) and
resorufin palmitate had the lowest (14.3 %). However, the reaction yield did appear to be
influenced by both fatty acid and fluorophore.

For both resorufin and DDAO, the

reaction yield was higher for arachidonate conjugates (19.9% and 65 %, respectively)
versus palmitate conjugates (14.3% and 33%, respectively). Despite this observation,
reaction yields are a function of many factors and the observed differences between
fluorophores and fatty acid may be related to differences in starting material purity,
adding temperature, side reactions such as dehydrochlorination, along with unidentified
mechanisms.
The colored nature of these compounds allowed for easy visual monitoring of
both reaction progress and separation using column chromatography. The use of U.V.
light to monitor progress in the column increased the ability to visually separate product
from starting material. Because the product traveled faster than the starting material, it
was possible to adjust the ratio of hexanes/ethyl acetate in each synthesis in real time in
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order to maximize separation. Following purification of individual probes with column
chromatography, structures were confirmed with mass spectrometry and 1H nuclear
magnetic resonance (1H NMR). Because of the asymmetry present in the fluorophore
DDAO, two tautomeric forms arising from proton transfer between the hydroxyl and
ketone groups are possible. However, despite this tautomerization, 1H NMR analysis did
not show a mixture of isomers indicating only one product was obtained. Previous
literature indicated that substitution of the hydroxyl on the chlorinated ring occurred to a
much higher extent (Warther et al. 2010, Duo, Goddard-Borger, and Withers 2014).
All fluorophores demonstrated the ability to be quenched through fluorescence
measurements in protonated vs. unprotonated states. In addition, hydrolysis with NaOH
demonstrated the ability to restore fluorescence for each esterified fluorophore. For
DDAO arachidonate, we demonstrated that a pancreatic phospholipase, sPLA2 GIB, can
also lead to probe activation. This will be explored in more detail in Chapter 4.
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Chapter 4: In Vitro Evaluation of Probe Activation and Specificity
4.1

Introduction
cPLA2 is overexpressed in numerous cancers and is implicated in the

development of resistance to estrogen receptor targeted therapy of breast cancer (Caiazza,
Harvey, and Thomas 2010, Murakami et al. 2011, Meyer et al. 2004, Hong et al. 2001).
In breast cancer, cPLA2 expression is correlated to the molecular subtype, with higher
expression in basal-like cancer versus luminal-like cancer (Caiazza et al. 2011). In
addition, levels of the downstream metabolite of cPLA2, glycerophosphocholine (GPC),
have been found to be elevated in basal-like compared to luminal-like breast cancer, and
this has been linked to elevations in cPLA2 gene expression (Moestue et al. 2010).
Molecular imaging of cancer offers the potential to probe alterations in enzyme
expression and activity in vivo, providing potentially relevant functional information for
clinical assessment. In a research setting, molecular imaging agents allow for the
elucidation of unknown biological tumor pathways and can serve as companion
diagnostics for the development of novel therapeutics (Weissleder 2006, Willmann et al.
2008). Activatable fluorophores for molecular imaging have been of increased interest
(Tung et al. 2004, Kamiya et al. 2007, Beatty et al. 2013, Setsukinai et al. 2003, Urano et
al. 2011). In contrast to targeted fluorophores, which rely on selective tumor
accumulation in combination with rapid systemic clearance to facilitate contrast,
activatable fluorophores generate high signal to noise due to selective activation in areas
of interest, typically through specific enzymatic cleavage (Rao, Dragulescu-Andrasi, and
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Yao 2007). This allows for the cleavage of multiple fluorescent substrates resulting in
increased signal amplification and high detection sensitivity. In addition, this provides
the ability to quantitate target activity in addition to enzyme expression.
Activatable fluorophores have been previously targeted towards phospholipases C
and A2 through incorporation of fluorophores and complimentary quenchers into the
backbone of a phospholipid (Popov et al. 2010, Mawn et al. 2011). In the design for
PLC, Pyropheophorbide a (Pyro), a NIR fluorophore, was esterified to the sn-2 position
and the head group was replaced with the NIR black hole quencher, BHQ-3. Further
alteration of this structure found that incorporation of a 12-carbon spacer between Pyro
and the glycerol backbone shifted specificity away from PLC and towards sPLA2 group
IB. Utilizing this probe design to generate a cPLA2 selective agent proved challenging.
cPLA2 structural based analysis has identified a small pocket where the head group lies
during lipolysis and it is likely a large quencher would decrease activity (Dessen et al.
1999). In addition, arachidonic acid at the sn-2 position would be necessary to generate
specificity for cPLA2. Therefore, a simpler probe design was needed.
Previous studies have shown that a caged fluorescent molecule, 7-HC is cleavable
by purified cPLA2 resulting in the generation of fluorescence (Huang et al. 1994, Pickard
et al. 1996). The fluorescence release occurred at an identical rate to enzymatic cleavage
of 14C-labeled endogenous phospholipids, suggesting that the glycerol backbone and head
group are not absolutely required for cPLA2-mediated cleavage. Due to the chemical
nature of fluorescence quenching, in which covalent molecular bonding alters the
delocalized electronic structure necessary for fluorescence, caged fluorophores can
53

theoretically achieve higher levels of quenching than spatially FRET or contact quenched
fluorophores, thus minimizing background signal. However, the low wavelength
emission of 7-HC limits its in vivo potential. Fluorophores which fluoresce in the NIR
window, a region of the electromagnetic spectrum with minimal absorption from
hemoglobin and water, are more suitable for in vivo imaging (Weissleder 2001).
In this Chapter, we assess the three cPLA2 caged red-shifted fluorophores,
described in Chapter 3, which were synthesized based on the design of 7-HC. In
addition, we assess the functionality of the two control probes in which palmitic acid was
esterified. Synthesized caged fluorophores contain only a fatty acid esterified to a small
molecule fluorophore, therefore it must be evaluated for each fluorophore whether
phospholipase activation can occur without the presence of a glycerol backbone and
phosphorylated head group. Due to the ability of purified cPLA2 to cleave 7-HC, we
hypothesized that similar small molecule fluorophores esterified to a fatty acid will also
be cleavable by PLA2. Additionally, we hypothesized that arachidonic acid, but not
palmitic acid, incorporated fluorophores will be cleavable by cPLA2.
Using purified porcine group IB sPLA2 (sPLA2 GIB), which has no specificity
for arachidonic acid, we first assessed the activatable fluorophores for their ability to
undergo enzyme-mediated cleavage in vitro. We then assessed whether incorporation of
arachidonic acid conferred selectivity towards cPLA2 in live cell assays using breast
cancer cell lines that express high levels of cPLA2. The enzymatic specificity to cPLA2
was assessed using inducing agents and inhibitors of the enzyme. In addition, we probed
whether varying the degrees of cPLA2 expression correlates with probe activation. In
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breast cancer, it has been shown that cPLA2 varies with breast cancer subtype, with
basal-like cancer expressing higher levels than luminal-like cancer (Caiazza et al. 2011).
We therefore used cell lines representing the three major subtypes of breast cancer to
evaluate whether activity correlates with cPLA2 expression. Finally, we utilized Cluster
Regularly Interspaced Short Palindromic Repeats (CRISPR) knockdown to more
specifically assess the role of cPLA2 in probe activation.
The fatty acid caged fluorophores are not soluble in aqueous media. Therefore a
method of solubilization was needed for delivery and enzymatic evaluation. Since
cPLA2 acts preferentially on phosphatidylcholine rich biological membranes (Murakami
et al. 2011), we decided to use artificial phosphatidylcholine rich liposomes for in vitro
analysis with purified enzyme. Egg phosphatidylcholine liposomes were therefore used
as a delivery vehicle for phospholipase probes. For in vitro studies, egg
phosphatidylcholine liposomes were generated (see Chapter 2: Methods) with the probe
incorporated at a mole fraction of 0.1. For experimental studies the amount of agent
added is referred to in nmol of activatable probe.
4.2

Results

Activation in the presence of sPLA2 GIB
sPLA2 GIB is a pancreatic digestive enzyme that functions to break down
ingested phospholipids for intestinal absorption (Dennis et al. 2011). sPLA2 GIB has no
specificity for incorporated fatty acids, however it has high phospholipase activity.
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Therefore, using purified sPLA2 GIB, we evaluated the ability of synthesized caged
fluorophores to undergo phospholipase-mediated cleavage.
To test for sensitivity to phospholipase cleavage, 1 nmol of probe was incubated
with varying concentrations of sPLA2 GIB in pH 7.4 Tris buffer containing 1.1 mM
CaCl2. Fluorescence generation was monitored as a function of time (Figure 4.1).
Naphthofluorescein diarachidonate displayed a low initial fluorescence (Figure 4.1A).

Figure 4.1. Cleavage and fluorescence generation of candidate probes by a nonselective
phospholipase (sPLA2 GIB). Fluorescence generation is shown with time in the presence of increasing
concentrations of sPLA2 GIB for naphthofluorescein arachidonate (A), resorufin arachidonate (B),
resorufin palmitate (C), DDAO arachidonate (D), and DDAO palmitate (E). One unit is equivalent to the
amount of enzyme producing 1 μmol of free fatty acid per minute at pH 8 and at 40 °C.
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Addition of sPLA2 GIB resulted in increased fluorescence generation that positively
correlated with enzyme concentration. However, the relative fluorescence units (R.F.U.)
were low, remaining under 20 R.F.U. even for the maximum concentration of enzyme
added.
Resorufin arachidonate and resorufin palmitate both resulted in increased
fluorescence with time, which was positively correlated with the concentration of sPLA2
GIB (Figure 4.1B,C). A high initial fluorescence was observed in both arachidonate and
palmitate activation studies. Initial fluorescence was higher in the presence of enzyme
than in control wells without added phospholipase. However, even in enzyme-free
controls, initial fluorescence was fairly high and increased with time.
DDAO arachidonate and palmitate both showed activation in the presence of
sPLA2 GIB that positively correlated with enzyme concentration (Figure 4.1D,E). Initial
fluorescence of both DDAO arachidonate and DDAO palmitate was low (less than 100
R.F.U.), and a significant time-dependent increase in fluorescence was observed in the
presence of sPLA2 (p = 5.7 × 10−26 and p = 2.8 × 10−14, respectively, for 100 units sPLA2
at 720 min).
In order to confirm that DDAO arachidonate and palmitate fluorescence
activation resulted directly from phospholipase activity, experiments were performed
using a sPLA2 inhibitor, LY311727 (Figure 4.2). In the presence of LY311727,
fluorescence generation was reduced for both probes (Figure 4.2A,B). Quantitation of the
final fluorescence intensity at 720 min (Figure 4.2C) showed that both DDAO
arachidonate and DDAO palmitate fluorescence were significantly (p = 1.4 × 10−11 and p
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Figure 4.2. DDAO fluorescence generation is attenuated by the sPLA2 inhibitor LY311727. The
fluorescence generated by 100 units of sPLA2 was inhibited by the addition of 100 μM of the sPLA2
inhibitor LY311727 for both DDAO arachidonate (A) and DDAO palmitate (B). (C) Quantifying the
fluorescence at 720 min shows that LY311727 significantly inhibits the final fluorescence intensity of
DDAO arachidonate (p = 1.4 × 10−11) and DDAO palmitate (p = 3.2 × 10−7 ). In the absence of enzyme,
DDAO arachidonate gives significantly higher fluorescence (p = 3.1 × 10−11) than DDAO palmitate. No
significant difference exists in the final fluorescence between DDAO arachidonate and DDAO palmitate
in the presence of 100 units of sPLA2.

= 3.2 × 10−7, respectively) reduced in the presence of LY311727. The final fluorescence
intensity of DDAO arachidonate was not significantly different from that of DDAO
palmitate. Due to the high degree of activation, high initial quenching, and low aqueous
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hydrolysis observed, DDAO arachidonate was chosen for future analysis of cPLA2
activity in combination with the control probe, DDAO palmitate.
Optimization of liposomal formulation
In order to optimize DDAO arachidonate activation and to minimize aqueous
hydrolysis, the formulation of the liposomes was varied and probe cleavage in the
presence of sPLA2 GIB was assessed. Delivery of probe in DMSO was also assessed as
an additional control. In all cases, the
concentration of probe was kept constant
at 0.2 nmol of probe per well in a 96 well
plate. Mole fractions of 0.01, 0.05, 0.1,
and 0.2 were tested (Figure 4.3).
There were no large differences in
aqueous mediated hydrolysis for all
conditions tested including a DMSO
vehicle control (Figure 4.3A). However, a
high difference in cleavage sensitivity was
noted when incubated in the presence of
100 units sPLA2 GIB (Figure 4.3B). It
was observed that a DDAO arachidonate
Figure
4.3.
Optimization
of
liposomal
formulation. A) Aqueous hydrolysis of DDAO
arachidonate
incorporated
into
egg
phosphatidylcholine liposomes at varying mole
fractions. B) sPLA2 mediated hydrolysis (100
Units) of DDAO arachidonate incorporated into
liposomes of varying mole fractions.
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mole fraction of 0.05 resulted in the
highest levels of cleavage. Increasing the
mole fraction to 0.1 or 0.2 resulted in

Figure 4.4. Cellular activation of DDAO arachidonate and DDAO palmitate. DDAO
arachidonate and DDAO palmitate were incubated with 4175-Luc+ cells for 30 min (A)
and for 3 h (B). Wide field fluorescent microscopy was performed to visualize free
DDAO fluorescence. Nuclei were counterstained with Syto 9. Separate and merged
fluorescence images are shown with yellow indicating overlap of fluorescence in the
merged image. (C) Fluorimetry was used to quantify DDAO fluorescence as a function of
time and demonstrated significantly increased fluorescence at 3 h from DDAO
arachidonate relative to DDAO palmitate (p = 1.3 × 10 −6 ).
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decreased fluorescence generation with time. The DDAO arachidonate / DMSO vehicle
control showed slow activation with time that was comparable to aqueous
mediated hydrolysis. This is consistent with PLA2 requiring a phospholipid membrane
in order to act. Egg phosphatidylcholine liposomes with a mole fraction of 0.05 probe
were further assessed for the effects of extrusion on fluorescence generation. Liposomes
were prepared as previously described (see Chapter 2: Methods) and then subjected to
extrusion through a sterile 0.2 µm filter. Following extrusion it was found that
fluorescence activation in the presence of sPLA2 was significantly decreased (data not
shown). Therefore, polydisperse liposomes without extrusion were used in future
experiments at a mole fraction of 0.05. Dynamic light scattering indicating an average
size of 295.55 nm with a polydispersity of 187.65 nm.
DDAO arachidonate activation in a cPLA2 expressing breast cancer cell line
The activity of DDAO arachidonate was further evaluated in a breast cancer cell
line expressing high levels of cPLA2. 4175-Luc+ is a triple-negative breast cancer cell
line derived from a murine lung metastasis of the MDA-MB-231 line and engineered to
express luciferase (Minn et al. 2005). MDA-MB-231 cells have previously been shown to
have increased cPLA2 activity consistent with the increased cPLA2 expression in triple
negative basal-like breast cancer (Caiazza, Harvey, and Thomas 2010). 4175-Luc+ cells
were incubated with DDAO arachidonate or DDAO palmitate for up to 3 h and costained with the nuclear stain Syto 9. The cells were analyzed with wide field
fluorescence microscopy (Figure 4.4). At 30 min, weak intracellular fluorescence from
DDAO arachidonate was observable with no fluorescence visible from DDAO palmitate
(Figure 4.4 A). At 3 hours, strong intracellular fluorescence was seen from DDAO
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arachidonate; however, there was still no fluorescence in cells incubated with DDAO
palmitate. DDAO arachidonate fluorescence was dispersed throughout the cytoplasm but
with high perinuclear fluorescence, consistent with the subcellular location of cPLA2
activity (Figure 4.4B). In order to quantitate activation, the experiment was repeated
using fluorimetry to measure fluorescence (ex/em: 600/660 nm) with time (Figure 4.4C).
Quantitation showed a strong time-dependent increase in fluorescence in cells incubated
with DDAO arachidonate, whereas little change was observed in DDAO palmitate
incubated cells. Unlike the nonselective sPLA2 GIB cleavage studies shown in Figure
4.2, DDAO arachidonate displayed a significantly (p = 1.3 × 10−6) higher final
fluorescence intensity in cells compared to that of DDAO palmitate.
In order to visualize the time dependence of fluorescence activation, a wide field
fluorescence microscope (EVOS FL Auto) equipped with a 37°C stage and a 5% CO2
incubation chamber was utilized. Following addition of DDAO arachidonate, the plate
was placed in the chamber for 30 minutes to adjust to the environment. Fluorescence
activation was then measured over the course of 70 minutes (Figure 4.5A,B). Small
vesicles with high fluorescence were seen to appear and then disappear as fluorescence
became dispersed throughout the cytoplasm. Vesicles appeared to be localized around
the peri-nuclear region where cPLA2 is known to act (Evans et al. 2001, Nakamura et al.
2010). In one cell, vesicles can be seen forming initially close to the nucleus, then
migrated out towards the cytoplasm and dispersing (Figure 4.5B).
To determine whether the observed differences in probe activation were the result
of cPLA2, two agents that induce cPLA2 activity were employed: ionomycin and
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Figure 4.5. DDAO arachidonate activation with time. Wide field fluorescence microscopy
was used to visualize the subcellular activation of DDAO arachidonate with time. DDAO
activation is shown in red, Syto 9 nuclear staining is shown in green. A) Fluorescence
accumulation can be seen with time dispersed throughout the cytoplasm and in small vesicles
surrounding the nucleus B) Cellular activation of DDAO arachidonate in one cell showed initial
appearance of bright vesicles surrounding the nucleus which migrated to the cytoplasm resulting
in dispersed fluorescence accumulation.
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hydrogen peroxide. Ionomycin is a calcium ionophore, which when incubated with cells
leads to calcium release from intracellular stores into the cytosol. cPLA2, which resides
in the cytosol, requires calcium for translocation to membranes where it can act on
membrane localized phospholipids (Burke and Dennis 2009, Murray-Whelan et al. 1995).

Figure 4.6. cPLA2 enzymatic induction and inhibition. cPLA2 activity was induced through either
H2O2 (A) or ionomycin (B). Fluorescence generation was monitored with time. DDAO arachidonate
showed significant enhancement of fluorescence in the presence of H 2O2 (p = 2.9 × 10−6 ) and ionomycin
(p = 1.9 × 10−7 ), whereas DDAO palmitate did not show any significant changes in fluorescence. (C)
Phospholipase inhibitors were incubated with cells for 4 h, cells were washed in PBS, and fresh medium
containing either DDAO arachidonate or DDAO palmitate was added. Fluorescence was recorded
following 30 min of incubation. AACOCF3 treatment resulted in a significant (p = 0.003) reduction of
fluorescence relative to that of the control. BEL and LY311727 did not alter fluorescence significantly.
No significant changes in fluorescence were recorded in the presence of DDAO palmitate.
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Previous work has indicated hydrogen peroxide is a potent activator of cPLA2 activity,
partly due to phosphorylation through the MAPK pathway (van Rossum et al. 2004).
Incubation of 4175-Luc+ cells with either ionomycin (2 μM) or hydrogen peroxide (300
μM) in the presence of DDAO arachidonate resulted in a significant (p = 1.9 × 10−7 and p
= 2.9 × 10−6, respectively) increase in the final relative fluorescence (Figure 4.6A,B).
However, neither ionomycin nor hydrogen peroxide had a significant effect on DDAO
palmitate fluorescence. It was noted that at 3 h, cells treated with ionomycin began
showing signs of stress, most notably rounding of the cells and detachment from the plate
to a small extent. It is possible that the slight nonsignificant increase in DDAO palmitate
fluorescence could be attributed to increased light penetration resulting from rounded up
cells. Phospholipase specificity was further evaluated by monitoring fluorescence
following incubation with several phospholipase inhibitors (Figure 4.6C). Inhibitors were
added to 4175-Luc+ cells for 4 h at a concentration of 10 μM, cells were then washed in
PBS, and fresh medium containing either DDAO arachidonate or DDAO palmitate was
added. Fluorescence (ex/em: 600/660 nm) was measured following 30 min of incubation.
Arachidonyl trifluoromethyl ketone (AACOCF3), a cPLA2 and iPLA2 selective
inhibitor, resulted in a significant reduction in DDAO arachidonate fluorescence
compared to that of untreated controls (p = 0.003). Bromoenol lactone (BEL), an iPLA2
selective inhibitor, resulted in no significant change in fluorescence. These data indicate
that the fluorescence inhibition caused by AACOCF3 is a direct result of cPLA2 activity
and not iPLA2 activity. In vitro studies (Figures 4.1 and 4.2) indicated that DDAO
arachidonate is also susceptible to cleavage by sPLA2. Therefore, to control for sPLA2
selective activation, the sPLA2 inhibitor LY311727 was used. A small decrease in
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fluorescence was witnessed in the presence of LY311727; however, this was not
significant. DDAO palmitate gave no significant changes in fluorescence in the presence
of any of the inhibitors.
To further evaluate the specificity of DDAO arachidonate, a highly potent cPLA2
inhibitor, AVX-235, was used. Cells were incubated with 10 µM AVX-235 for two
hours prior to analysis. DDAO arachidonate or DDAO palmitate was added to initiate

Figure 4.7. Inhibition of DDAO arachidonate by AVX-235. DDAO arachidonate and DDAO palmitate
activation was measured as a function of time in 4175-Luc+ cells in the presence of 10 µM AVX-235, a
potent cPLA2 inhibitor, or DMSO vehicle control. A significant decrease (p=0.006) of fluorescence
corresponding with 20% inhibition was observed for DDAO arachidonate. No significant changes were
seen for DDAO palmitate.
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the reaction and fluorescence generation was monitored with time. AVX-235 resulted in
a significant inhibition in the generation of fluorescence with time (p=0.006) with no
significant inhibition of DDAO palmitate (Figure 4.7).
Activation of DDAO arachidonate in varying breast cancer subtypes
DDAO arachidonate was evaluated in a series of breast cancer cell lines
previously described to differ in their expression of cPLA2. Three breast cancer cell
lines were chosen to represent the three major subtypes of breast cancer. MDA-MB-231
is a basal-like cell line representing triple negative breast cancer. SKBR3 is a HER2
expressing cell line representing HER2-like breast cancer. MCF-7 is a estrogen receptor
positive cell line representing luminal-like
breast cancer. In addition, we also used the
4175-Luc+ cell line, a metastatic derivative
of the MDA-MB-231 cell line, which is
highly tumorigenic.
Cell lines were analyzed by
immunoblot to determine the relative
protein levels of cPLA2 (Figure 4.8).
Consistent with previous literature, it was
Figure 4.8. Immunoblot of cPLA2 in breast
cancer cell lines. A) cPLA2 and β-tubulin protein
expression levels. B) Quantitated ratio of cPLA2 /
β-tubulin.

found that MCF-7 cells contain the lowest
levels of cPLA2, with SKBR3 cells having
two fold higher expression and MDA-MB-
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231 cells having six fold higher expression. 4175-Luc+ cells have the highest cPLA2
expression, even greater than the parent cell line, MDA-MB-231.
To determine whether cellular protein levels correlated with cPLA2 activity we
seeded cells in 96 well black-wall clear bottom plates at concentrations optimized to
achieve ~80% confluency in 48 h. To test for specificity, the cPLA2 inhibitor AVX-235
or vehicle control was added 2 hours prior to the addition of either DDAO arachidonate
or DDAO palmitate. Fluorescence was measured at four hours using the LI-COR
Odyssey® CLx imaging system (700 nm channel) and quantitated relative to the mg of
protein present per well determined using a Qubit® protein assay (Figure 4.9). 4175Luc+ gave the highest fluorescence activation of DDAO arachidonate, followed by
MDA-MB-231. SKBR3 displayed fluorescence less than that of MDA-MB-231 and
MCF-7 cells displayed the lowest relative fluorescence. AVX-235 significantly inhibited
the fluorescence of 4175-Luc+ and MDA-MB-231 (p = 0.006 and 0.03, respectively). A
trend towards reduced fluorescence was seen for SKBR3 and MCF-7 cells in the
presence of AVX-235, however this was not significant. In all cases, DDAO palmitate
fluorescence was significantly less than that of DDAO arachidonate. Using the
assumption that DDAO palmitate activation is a function of non-cPLA2 mediated
hydrolysis, the R.F.U. / mg protein was adjusted by subtraction of the DDAO palmitate
fluorescence and plotted as relative cPLA2 activity (Figure 4.10A). A close correlation
(R2 = 0.9633) between fluorescence activation and protein expression can be seen (Figure
4.10B).
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Figure 4.9. Inhibition of cPLA2 in a panel of breast cancer cell lines with AVX-235. Four breast
cancer cell lines representing the three most common breast cancer subtypes were incubated with DDAO
arachidonate or DDAO palmitate in the presence or absence of 10 µM AVX-235, a potent cPLA2
inhibitor. Fluorescence was acquired after four hours on a LI-COR Odyssey CLx imaging system (700
nm channel). Significant inhibition of DDAO arachidonate was observed for 4175-Luc+ and MDA-MB231 cells when incubated with AVX-235 (p = 0.006 and 0.03, respectively). No significant changes in
DDAO palmitate fluorescence were observed in all cell lines analyzed.

In order to confirm that measured signal is a result of cellular activation, we
repeated this study in the MDA-MB-231, SKBR3, and MCF-7 cell lines using confocal
fluorescence microscopy (Figure 4.11). Images were acquired at 4 hours and analyzed
with Image J. MDA-MB-231 resulted in the brightest fluorescence, followed by SKBR3,
with MCF-7 cells displaying the lowest fluorescence generation. AVX-235 treatment
resulted in decreased fluorescence in all cell lines for DDAO arachidonate. As observed
with spectroscopy, cells treated with DDAO palmitate displayed weak fluorescence
making visualization difficult.
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Analysis of images costained with nuclear HOESCHT2388 reveals differences in
cytosolic distribution of fluorescence (Figure 4.12). MDA-MB-231 cells display
fluorescence evenly dispersed throughout the cytosol. SKBR3 displays fluorescence
concentrated in small cytosolic vesicles. MCF-7 displays low cytosolic fluorescence and
uniquely shows evenly dispersed fluorescence in the cellular membrane.
Finally, a genetic knockdown using Cluster Regularly Interspaced Short
Palindromic Repeats (CRISPR) technology was generated through transfection of 4175Luc+ cells with a cPLA2 targeted knockout vector (Santa Cruz Biotechnology). This
vector encoded for CRISPR associated protein 9 (Cas9), 3 Cas9 guide RNAs targeted
towards cPLA2, and green fluorescent protein (GFP) (Figure 4.13A). Positively
transfected cells, determined through the expression of GFP, were separated using
fluorescence-activated cell sorting (Figure 4.13B). Cells were expanded and analyzed for
protein expression (Figure 4.14A). A significant reduction in cPLA2 expression
(approximately 40%) was observed in CRISPR treated cells versus non-transfected.
DDAO arachidonate and DDAO palmitate activation within these cells was determined
with time (Figure 4.15A) and cPLA2 activity was quantitated at 120 min (Figure 4.15B).
A significant decrease in fluorescence was observed in cells treated with CRISPR/Cas9
knockout vector (p = 1.58 x 10-6).
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Figure 4.10. cPLA2 activity in breast cancer cell lines. A) cPLA2 activity in breast cancer cell lines
was calculated from Figure 4.9 by subtracting non-selective cleavage from the fluorescence of DDAO
palmitate. B) Activity levels relative to 4175-Luc+ were plotted versus cPLA2 expression relative to
4175-Luc+ (taken from Figure 4.8). A close correlation (R 2 = 0.9633) between activity and expression
was observed.
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Figure 4.11. Confocal fluorescence microscopy of DDAO arachidonate and palmitate
activation and inhibition. Fluorescence at four hours is shown as a heat map with brighter areas
indicating high fluorescence signal.

Figure 4.12. Confocal fluorescence microscopy of the subcellular distribution of DDAO
arachidonate. Fluorescence at four hours with DDAO fluorescence in green, and HOESCHT
33342 nuclear staining in blue. Images are not optimized for intensity comparison but for analysis
of subcellular distribution.
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Figure 4.13. cPLA2 genetic knockdown through CRISPR/Cas9. A) A cPLA2 targeted CRISPR/Cas9
vector encoding Cas9, 3 cPLA2 targeted guide RNAs, and GFP was purchased from Santa Cruz
Biotechnology. A vector containing scrambled guide RNAs was also purchased. B) Vector was
transfected into 4175-Luc+ cells and GFP expressing cells were separated using fluorescence-activated
cell sorting. A fluorescence cut-off of 102 was chosen based on the auto-fluorescence of non-transfected
cells (neg) and positive populations of cPLA2 (cPLA2) and scrambled (Ctrl) transfected cells were
isolated.
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Figure 4.14. cPLA2 expression in CRISPR transfected cells. A) Immunoblot of cPLA2 and βtubulin in non-transfected, cPLA2 CRISPR transfected, and scrambled CRISPR transfected cells. B)
Quantitation of relative cPLA2 expression in cell lines. Significant reduction of protein expression is
observed for cPLA2 transfected cells (p = 8.2 x 10 -7).

4.3

Discussion
In this Chapter, we determined the sensitivity of our synthesized DDAO probes to

phospholipase activation using purified enzyme and cells. Prior to the analysis for
specificity to cPLA2 activation, it needed to be ascertained whether all probes, including
the palmitic acid controls, were susceptible to phospholipase mediated cleavage. To
determine this, the probes were tested against sPLA2 GIB, a pancreatic digestive
phospholipase with no specificity towards arachidonic acid. It was observed that all
probes were activated with time in proportion to the concentration of sPLA2 added.
Similar to what was observed in the literature for 7-HC (Huang et al. 1994), these data
supports the concept that a glycerol backbone and phosphorylated head group are not
74

necessary for probe activation by PLA2. However, modification of the fluorophore and
fatty acid both led to observable effects on the degree of cleavage.
Naphthofluorescein diarachidonate displayed poor enzymatic activation, with the
final fluorescence intensity remaining under 20 R.F.U.s, even for the maximum
concentration of enzyme added. Naphthofluorescein diarachidonate was the largest
fluorophore synthesized, and it is possible that steric hindrance contributed to poor
enzymatic cleavage. In addition, naphthofluorescein has a pKa of 7.6, which may
contribute to the poor relative fluorescence observed at pH 7.4. At a pH of 8.0, it was
possible to increase the relative fluorescence generation 9-fold. Because of these
observed limitations, a naphthofluorescein dipalmitate control probe was not synthesized.
Resorufin arachidonate and resorufin palmitate both gave increased fluorescence
generation with time. However, a high initial fluorescence was observed indicating either
poor intramolecular quenching or rapid enzymatic hydrolysis. Even in controls
conducted without the addition of enzyme, initial fluorescence was fairly high and
increased over time. This would indicate that resorufin-conjugated fatty acids may be
susceptible to nonspecific aqueous hydrolysis in addition to enzymatic cleavage.
Similar to resorufin, DDAO arachidonate and palmitate both gave increased
fluorescence activation with time. Initial fluorescence of both DDAO arachidonate and
DDAO palmitate was low (less then 100 R.F.U.) indicating a high degree of initial
fluorescence quenching. In addition, minimal aqueous hydrolysis was observed
indicating DDAO arachidonate would be likely to give the largest signal to noise ratio.
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Figure 4.15. DDAO arachidonate and DDAO palmitate activation in CRISPR transfected cell lines.
A) Activation with time of DDAO arachidonate and DDAO palmitate in cPLA2, scrambled, and nontransfected cells. B) Quantitation of relative fluorescence at 120 min showing significant reduction in
cPLA2 targeted CRISPR transfected vector (p = 1.58 x 10 -6)

The large difference in initial fluorescence observed between DDAO and
resorufin conjugates may be due to steric or electrostatic protection by the two chloride
groups ortho to the ester bond in DDAO. This is consistent with previous literature
showing that 2,6-dichlorophenyl acetate has a hydrolysis constant that is 1.5 times lower
than that of phenol acetate (Nottebohm 2010). For DDAO arachidonate, a more rapid
initial rate of fluorescence activation was observed compared to the palmitate probe,
suggesting that arachidonate conjugation results in a more readily hydrolyzable
fluorophore. Because of DDAO’s high initial quenching and significant increase in
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fluorescence versus other fluorophores, it was chosen as our candidate cPLA2 probe for
further studies.
Inhibition of sPLA2 with LY311727 resulted in a significant decrease in the
generation of DDAO arachidonate and DDAO palmitate generated fluorescence
indicating activation is a direct result of enzyme activity. The final fluorescence intensity
was not significantly different between DDAO arachidonate and palmitate probes
indicating both probes are hydrolyzed to the same degree, albeit at different rates. As
expected, because sPLA2 GIB has no selectivity for arachidonic acid, no difference in
final fluorescence was observed. However, DDAO arachidonate in the absence of
enzyme did give significantly (p = 3.1 x 10-11) higher fluorescence than that of DDAO
palmitate indicating that DDAO arachidonate may be more sensitive to aqueous
hydrolysis. This may be an additional factor contributing to the differing rates of
enzymatic hydrolysis observed.
In a triple negative breast cancer cell line expressing high levels of cPLA2,
fluorescence generation in the presence of DDAO arachidonate and DDAO palmitate was
assessed with fluorescence microscopy and spectroscopy. To minimize the presence of
sPLA2, cells were washed 2x with PBS immediately prior to addition of probe. It was
observed that unlike sPLA2 mediated cleavage studies, breast cancer cells led to
significantly increased activation of DDAO arachidonate relative to DDAO palmitate.
Microscopy showed that the activation occurred intracellularly, with probe dispersed
throughout the cytoplasm but with high perinuclear fluorescence, consistent with the
subcellular location of cPLA2. The final fluorescence intensity, measured with
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fluorescence spectroscopy, was noted to be lower than the relative fluorescence achieved
through in vitro studies. This may be attributed to a combination of increased scattering
and absorption of light by cells and differences in enzyme concentration, along with
variations in cellular uptake. However, these results indicate that DDAO arachidonate
was specifically activated in 4175-Luc+ breast cancer cells, whereas DDAO palmitate
was not.
The specificity of the cPLA2 activity was probed through the use of cPLA2
inducing agents and inhibitors. Ionomycin and hydrogen peroxide, two known inducers
of cPLA2 resulted in a significant increase of DDAO arachidonate fluorescence but not
DDAO palmitate. AACOCF3, a mixed inhibitor for cPLA2 and iPLA2, resulted in
significant reduction of fluorescence generation implicating either cPLA2 or iPLA2 to be,
at least partially, responsible for cleavage. BEL, an iPLA2 selective inhibitor, had no
effect on fluorescence generation, nor did LY311727, a sPLA2 selective inhibitor.

In

addition, we explored the use of a highly potent cPLA2 inhibitor, AVX-235. In repeating
DDAO activation in the presence of inhibitor, we found a higher percentage of
fluorescence inhibition, compared to that with AACOCF3, was achievable with AVX235. Together these results suggest that although DDAO arachidonate is susceptible to
sPLA2 mediated cleavage in vitro, the fluorescence observed in cancer cells directly
results from cPLA2 activity. DDAO palmitate, being activated by sPLA2 to the same
extent as DDAO arachidonate, but not by cPLA2, served as a useful control for
nonselective cleavage when assaying cPLA2 activity. This was used further to assess
differences in cPLA2 in breast cancer subtypes.
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cPLA2 has been shown to vary in breast cancer subtypes with higher expression
in basal-like vs. luminal-like cancer. Through immunoblot analysis, we measured cPLA2
expression in four breast cancer cell lines ranging in molecular subtype. In agreement
with previously reported studies (Caiazza, Harvey, and Thomas 2010), we found that
triple negative breast cancer cells had the highest cPLA2 expression, HER2 expressing
cells had intermediate expression, and luminal-like cells had low expression. Analysis of
DDAO arachidonate activation in these cell lines correlated closely with relative cPLA2
expression levels, thus lending further evidence to the specificity of DDAO arachidonate
for cPLA2.
Inhibition of cPLA2 in cell lines using the inhibitor AVX-235 was shown to
significantly decrease the fluorescence generation of DDAO arachidonate in 4175-Luc+
and MDA-MB-231 cells. Although a trend towards decreased fluorescence was seen in
MCF-7 and SKBR3 cells, this was not significant. It is likely the lower fluorescence
signal present in MCF-7 and SKBR3 decreases the ability to measure significant
inhibition. When experiments were repeated using fluorescence confocal microscopy, a
clear drop in fluorescence was observed in all cell lines when incubated with AVX-235.
Confocal microscopy of the cell lines provided valuable insight into the
variability that is present in the sub-cellular location of DDAO arachidonate activation.
Differences in vesicle appearance and activation between cell lines may be an effect of
time, as was observed in Figure 4.5. The nature of these vesicles requires further
investigation. Liposomes can be incorporated into cells through two main processes
(Düzgünes and Nir 1999). Membrane fusion can occur between the cellular membrane
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and the liposomal membrane resulting in dispersion of probe throughout the cell.
Alternatively endocytosis of liposomes followed by fusion or lipid exchange could occur.
Depending on the extent of lipid exchange which occurs, transfer to lysosomal vesicles
and subsequent degradation is also possible and may be a cause of non-specific
activation. The presence of fluorescent vesicles in microscopic analysis indicates
endocytosis may be the main uptake mechanism employed.
Interestingly, confocal microscopy also revealed the presence of several bright
cells which saturated the image in all three cell lines analyzed. These cells all had
characteristic signs of stress including rounding up and detachment from the plate.
cPLA2 activation has previously been shown to be involved in apoptotic activation and
shown to be required for tumor necrosis factor (TNFα) induced apoptosis (Enari et al.
1996). Lipid droplet accumulation, a characteristic of cancer cells exposed to apoptosis
inducing anti-cancer agents (Delikatny et al. 2011), has also been linked to cPLA2
activity (Gubern et al. 2008). Whether the high fluorescence observed in microscopic
images is a result of cPLA2 activity associated with apoptosis requires further
investigation. However, this result highlights the potential utility of DDAO arachidonate
in the investigation of cell signaling and therapeutic response.
Finally, we sought to obtain a genetic knockout of cPLA2 through transfection
with a cPLA2 targeted CRISPR/Cas9 vector. Isolation and expansion of transfected cells
resulted in a partial knockdown of cPLA2 expression. Based on the mechanism of action
for CRISPR, it is likely we obtained a mixed population of 100% knockout and fully
cPLA2 expressing cells. However, this mixed population did result in reduced DDAO
80

arachidonate fluorescence indicating that cPLA2 gene expression is correlated to probe
activation. Future work will include isolation of a 100% knockout cell line that will be
used to determine the degree of non-specific activation involved in DDAO arachidonate
activation.
In summary, DDAO arachidonate appears to be specifically activated due to the
actions of cPLA2 in breast cancer cell lines. DDAO palmitate is not activated by cPLA2
and therefore serves as a useful control for non-cPLA2 mediated cleavage, including the
assessment of sPLA2 activity and aqueous hydrolysis. Analysis of DDAO arachidonate
in a panel of breast cancer cell lines indicates it may be useful for the in vivo molecular
imaging of cPLA2 in triple negative breast cancer.
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Chapter 5: In Vivo Activation of DDAO Arachidonate
5.1

Introduction
This Chapter explores the use of DDAO arachidonate for in vivo imaging of

breast cancer and the evaluation of its potential as a contrast agent for NIR fluorescence
guided surgery. In vivo molecular imaging of cancer allows for the phenotypic and
genotypic analysis of cancer while also providing anatomical tumor location. In a
research setting, this allows for the assessment of tumor biology while also providing a
model for the investigation of anti-cancer therapeutics (Willmann et al. 2008). In a
clinical setting, this allows for the real-time determination, monitoring and alteration of
treatment protocols (Weissleder 2006).
Fluorescence guided surgery is a field rapidly gaining momentum for its ability to
aid in the surgical resection of tumors. Fluorescence guidance has been shown to reduce
positive margins following resection and has been correlated to reduced risk of
reoccurrence and metastasis (Nguyen and Tsien 2013). Though promising, the majority
of contrast agents which have been evaluated accumulate through the EPR effect and
provide little functional information outside of vasculature disruption. Activatable
fluorophores have been shown to be capable of engineering specificity towards cancer
markers and because they do not rely on accumulation they can generate a higher
theoretical signal to noise (Rao, Dragulescu-Andrasi, and Yao 2007).
Improved contrast agents for breast cancer are desperately needed as the
percentage of positive margins seen following surgery range from 5-49% based on the
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study performed (Vahrmeijer et al. 2013). cPLA2 has been shown to be a molecular
target associated with breast cancer. cPLA2 varies between subtypes with higher
expression in basal-like triple negative breast cancer (Caiazza, Harvey, and Thomas
2010). Elevated levels of cPLA2 in luminal-like breast cancer have been implicated in the
development of resistance to hormonal therapy. In support of this, luminal-like breast
cancer patients with elevated cPLA2 had a statistically decreased rate of overall survival
(Caiazza et al. 2011). Therefore, activatable fluorophores targeted towards cPLA2 may
prove useful in the surgical resection of breast cancer and the discernment of aggressive
breast cancer from less aggressive forms in real-time.
In Chapter 4, we identified DDAO arachidonate as an activatable fluorophore
with specificity towards cPLA2. In this chapter, we explore DDAO arachidonate for its
use in the in vivo imaging of breast cancer. We first explore the effects of systemic
delivery of DDAO arachidonate. Next we compare different tumor tissues for activation
in ex vivo fluorescence studies. Final we explore DDAO arachidonate in a surgical
model through i.p. injections close to the tumor site.
5.2

Results
4175-Luc+ breast cancer cells were previously derived from MDA-MB-231 cells

through harvesting and re-culturing of a lung metastasis from mice bearing tumor
xenografts (Minn et al. 2005). As a result, 4175-Luc+ breast cancer cells grow readily in
mice and metastasize to lung. We have shown that 4175-Luc+ cells have high levels of
cPLA2 and can activate DDAO arachidonate but not the DDAO palmitate control probe.
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In order to assess the efficacy of DDAO arachidonate in vivo, 4175-Luc+ cells were
grown as tumor xenografts in the hind right flank of athymic mice.
Following the establishment of a palpable tumor, mice were switched to a low
fluorescence chow (LabDiet 5V02) for 48 hours to reduce background fluorescence.
DDAO arachidonate or DDAO palmitate (40 nmol) was injected in egg
phosphatidylcholine liposomes (MF 0.05). Fluorescence images (ex/em: 640/680) were
acquired over 48 hours (Figure 5.1). The results show that high fluorescence is
observable throughout the entire mouse making discernment of tumor fluorescence

Figure 5.1. Challenges of whole body fluorescence imaging. Mice bearing 4175-Luc+ tumor
xenografts were injected i.v. with 40 nmol of DDAO arachidonate containing liposomes (MF 0.05).
Fluorescence is shown with time (ex/em: 640/680). High background fluorescence is seen throughout the
mouse which decreases slightly up to 48 hours.
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difficult. This initial result highlights the challenges associated with whole body
fluorescence imaging. DDAO fluorescence lies on the lower wavelength edge of the NIR
window, where there may still be significant absorption from tissue. In addition, tissue
auto-fluorescence from elastin, collagen, and other endogenous biological fluorophores is
high at wavelengths less than 600 nm and the tails of the emission spectra may overlap
with DDAO fluorescence (Hilderbrand and Weissleder 2010). Finally, we have shown in
vitro that pancreatic sPLA2 GIB can activate both DDAO arachidonate and DDAO
palmitate. As a result, probe activation by sPLA2 GIB in the small intestines can occur
resulting in signal overlap with surrounding tissue, increasing overall background.
Spectral unmixing techniques have been developed for the separation of different
fluorescent signals in vivo based on their characteristic spectra (Xu and Rice 2009). By
imaging fluorophores separately using various different emission and/or excitation filters,
characteristic fluorescence spectra can be generated and saved for each fluorophore. In
vivo, these spectra can be applied to images with multiple fluorophores containing
overlapping emission spectra in order to unmix the individual fluorescence signals. This
technique can be used to separate auto-fluorescence from actual signal, increasing
detection specificity.
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Figure 5.2. Whole body fluorescence imaging of DDAO arachidonate with spectral unmixing. A)
Mice bearing 4175-Luc+ tumor xenografts were injected i.v. with 40 nmol of DDAO arachidonate
containing liposomes (MF 0.05). Fluorescence is shown with time (ex/em: 640/680) using spectral
unmixing post-processing to remove auto-fluorescence. The tumor can be seen in the bottom right flank
of the mouse indicated with an arrow. B) Quantification of tumor fluorescence with time.
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A filter scan was performed using two excitation filters (570 and 640 nm) and a
series of emission filters separated by 20 nm for each excitation (excitation 570 nm:
emission 620 - 780 nm; excitation 640 nm: emission 680 - 780 nm). A spectral signal
was acquired for DDAO in a 1.5 mL Eppendorf in PBS, pH 7.4, and auto-fluorescence
using a dorsal facing mouse with no treatment. Using the PerkinElmer LivingImage
software, these spectra were applied to the images in Figure 5.1 and an unmixed
fluorescence image of DDAO arachidonate and palmitate was obtained (Figure 5.2).
Spectral unmixing resulted in a substantial reduction in auto-fluorescence. As expected,
intestinal fluorescence was observed as a result of DDAO arachidonate or palmitate
activation in the intestines. Because this signal arises from DDAO fluorescence, it was
not removed through spectral unmixing. However, the location of the tumor far from the

Figure 5.3. Biodistribution of DDAO arachidonate and DDAO palmitate. A) Fluorescence (ex/em:
640/680) of DDAO arachidonate in excised tissue. B) Quantification of the radiant efficiency for excised
tissue. C) Expanded view of organ fluorescence with digestive organs removed.
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Figure 5.4. Elimination of DDAO arachidonate and DDAO palmitate. A) Whole body spectrally
unmixed fluorescence of ventral facing mice over 2 days following injection i.v. with 40 nmol of DDAO
arachidonate. B) Quantification of DDAO arachidonate and DDAO palmitate elimination through
measurement of whole body fluorescence spectrally unmixed signal from ventral facing mice.

intestinal fluorescence allows the tumor signal to be resolved. As digestion of
fluorophore occurs, it is passed further down the intestines, and the signals begin to
overlap (seen most notably at 48 hours). Regardless, tumor fluorescence can be observed
from both DDAO arachidonate and DDAO palmitate fluorophores (n=3 DDAO
arachidonate, n=2 DDAO palmitate). This fluorescence was significantly higher for
DDAO arachidonate fluorescence at 4 and 6 hours relative to DDAO palmitate
fluorescence (p = 0.002 and 0.02, respectively). This significance is lost at 24 and 48
hours as both signals increase.
Following the image acquisition at 48 hours, mice were euthanized and individual
organs were excised, rinsed in PBS, and imaged for fluorescence (ex/em: 640/680 nm)
(Figure 5.3). As expected, strong fluorescence was observed in both the small and large
intestines. In addition, stomach fluorescence was shown to also be high. Tumor
fluorescence was observed from both DDAO arachidonate and DDAO palmitate and was
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greater than other non-digestive organs
analyzed. Though not significant, DDAO
arachidonate fluorescence was slightly
greater than DDAO palmitate in excised
organs at 48 h. In analysis of other organs,
DDAO arachidonate tumor fluorescence
was significantly higher than heart, lungs,
kidney, and muscle (p = 0.02, 0.03, 0.04,
0.04, respectively). DDAO palmitate
trended towards higher fluorescence but
was not significantly larger than any other
organ. The calculated tumor / muscle ratio
Figure 5.5. Ex Vivo tumor painting. Orthotopic
4175-Luc+ tumors were excised from mice, sliced,
and cultured ex vivo in DMEM (5% CO2, 37°C).
DDAO arachidonate, DDAO palmitate, or saline
was painted onto tumors and left to incubate 3
hours. Tumors were then imaged for fluorescence
in the
LI-COR Pearl Impulse imaging system
(700 nm channel).

of DDAO arachidonate was found to be
significant and determined to be 2.14.
In a separate study, whole body
fluorescence imaging with spectral

unmixing of ventral facing mice was conducted as a function of time following injection
of either DDAO arachidonate (n = 4) or DDAO palmitate (n = 4) (Figure 5.4). There was
high variability of the total fluorescence between each mouse in this experiment leading
to larger error bars in the data. However, a common trend of significantly decreased
fluorescence was observed at 24 hours relative to the maximum signal at 6 hours for
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DDAO arachidonate (p = 0.02). Therefore the majority of probe was cleared within this
time.
Despite the ability to resolve tumor fluorescence with spectral unmixing, high
background and intestinal fluorescence remained challenging. Furthermore, the low
tumor signal intensity at 48 hours compared to intestinal signal indicated a relatively low
delivery of fluorophore to tumor. In order to assess tumor activation of probe directly
and to avoid issues of delivery and background fluorescence, ex vivo tumor painting
studies were conducted.
For these experiments, mice were injected orthotopically with 4175-Luc+ cells.
Following the formation of a palpable tumor, mice were euthanized. Tumor tissue (n=2)
was excised, sliced into approximately 1
mm thick sections for the appropriate
number of conditions, and placed into 24
well plates containing DMEM. The tissue
was placed at 37°C, 5% CO2 and 20 nmol
of DDAO arachidonate, DDAO palmitate,
or saline was pipetted evenly over the
surface of the tumor. The tumor was
incubated for 3 hours, washed twice in
Figure 5.6. Analysis of DDAO fluorescence in
the LI-COR Pearl Impulse Imaging system (700
nm channel).
DDAO was assessed for
fluorescence in TRIS buffer at pH 7.4 and pH 5.
Free buffer is shown as a control.

PBS, and fluorescence was acquired in a
LI-COR Pearl Impulse imaging system
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(700 nm channel) (Figure 5.5). Significantly greater fluorescence from tumors (n =2)
painted with DDAO arachidonate was observed compared to either DDAO palmitate or
saline (p = 7 x 10-6 and 6.5 x 10-6 respectively). A small activation was observed from
DDAO palmitate, which was significant over saline control (p = 4.5 x 10-4). Due to the
non-optimal excitation wavelengths in the Pearl Impulse imaging system, fluorescence of
DDAO was confirmed to be visible at pH 7.4 using this system (Figure 5.6).
Expanding on this study, we analyzed the differences in activation between 4175-

Figure 5.7. Ex Vivo Tumor Painting for comparison of breast cancer subtypes. A) 4175-Luc+, MCF7, and non-inoculated mammary fat pad were excised from mice, sliced and cultured ex vivo. 20 nmol
DDAO arachidonate containing liposomes (MF 0.05) were pipetted evenly onto the surface of tumors.
Fluorescence (ex/em: 640/680) was acquired with time. B) The final fluorescence relative to the amount
of tissue was quantitated.
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Figure 5.8. Intraoperative study of DDAO arachidonate. A) 4175-Luc+ cells were inoculated
into the lower left mammary fat pad and into the right shoulder. Following formation of a palpable
tumor, 40 nmol of DDAO arachidonate containing egg phosphatidylcholine liposomes (MF 0.05)
were injected i.p. directly under the tumor. After one hour the mice were euthanized, and dissected
to reveal the peritoneal cavity. The entire cavity was washed 1x in PBS and fluorescence (ex/em:
640/680) was acquired. White arrows indicate the location of tumor. B) The orthotopic tumor,
tumor bearing mammary fat pat, non-inoculated mammary fat pad, and shoulder tumor xenograft
were excised, rinsed in PBS and imaged for fluorescence (ex/em: 640/680). The experiment was
repeated with MCF-7 luminal-like cells. The images are shown on the same vertical scale in the
central Figure, and again on the right with the vertical scale expanded to optimize tumor
fluorescence.
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Luc+ (basal-like) and MCF-7 (luminal-like) orthotopic tumors. MCF-7 cells require
estrogen for growth. Therefore, one week prior to tumor inoculation, mice were
implanted subcutaneously with a slow release 17β-estradiol tablet. Following
development of palpable tumors, mice were euthanized. Tumor and non-inoculated
mammary fat pad (n = 3) were excised, sliced into approximately 1 mm thick sections for
the appropriate number of conditions, and placed in DMEM at 37°C, 5% CO2. DDAO
arachidonate (20 nmol) was pipetted evenly over the surface of the tumor. Fluorescence
was imaged on the IVIS spectrum as a function of time (ex/em: 640/680) (Figure 5.7).
Significant activation of DDAO arachidonate was observed in 4175-Luc+ tumor slices
versus MCF-7 and mammary fat pad at 30 min (p = 0.002 and 0.04 respectively) and 1
hour (p = 0.001 and 0.04 respectively).
It appears evident that high activation of DDAO arachidonate can be achieved in
triple negative breast cancer, however high background fluorescence following systemic
injection has thus far limited our ability to unequivocally determine tumor fluorescence in
vivo. Unlike targeted fluorophores that rely on selective accumulation, DDAO
arachidonate has the advantage that it can activate selectively in cancerous tissue.
Therefore, during surgical resection it may be possible to paint DDAO arachidonate onto
the tumor versus delivering i.v. In order to explore this, we sought to develop an
experimental model that could mimic this surgical painting.
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Tumors were grown orthotopically in the lower mammary fat pad. Shoulder
tumor xenografts were also implanted on the opposing side of the mouse. Following 21
days of growth, 40 nmol of DDAO arachidonate containing liposomes (MF 0.05) were
injected i.p. directly under the tumor in order to enhance delivery. After one hour, mice
(n = 3) were euthanized and the peritoneal cavity was exposed. The cavity was washed
with PBS to remove non-absorbed fluorophore and fluorescence (ex/em: 640/680) was
acquired on the IVIS Spectrum (Figure 5.8). Strong fluorescence from the area of the
tumor was observed (Figure 5.8A). Surgical resection of orthopic tumor, shoulder tumor
xenograft, inoculated mammary fat pad, and non-inoculated mammary fat pad was

Figure 5.9. Biodistribution of DDAO arachidonate 1 hour following i.p. injection. Organ
distribution of DDAO arachidonate is shown in under “Mouse 1”. A control mouse was injected with an
equal volume of saline. The legend of organs is shown on the right.
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performed. Organs were washed in PBS and ex vivo fluorescence (ex/em: 640/680)
indicated strong fluorescence from the orthotopic tumor, which was significantly greater
than fluorescence from the inoculated mammary fat pad, non-inoculated mammary fat
pad, and the shoulder tumor xenograft (outside the area of DDAO arachidonate injection)
(p = 0.002, 0.001, 0.001, respectively) (Figure 5.8B). One inoculated mammary fat pad
was noted to display high fluorescence. Repeating this experiment in mice bearing
luminal-like orthotopic tumors (n = 2) revealed significantly less activation (p = 0.01).
However, when viewed on an expanded scale, there was significant activation of MCF-7
tumors seen versus non-inoculated and inoculated mammary fat pad (p = 0.009 and 0.01,
respectively). Comparison of individual organs following i.p. injection of DDAO
arachidonate revealed high intestinal and stomach fluorescence as was observed
previously. This signal was also present in a non-treated control mouse (n = 1),
suggesting chow (despite being low fluorescence) still contributes to background
fluorescence (Figure 5.9).
5.3

Discussion
Following i.v. administration of DDAO arachidonate and DDAO palmitate

control, we were able to visualize time dependent changes in tumor fluorescence.
However, high background signal was apparent from fluorescence dispersed throughout
the animal. This fluorescence appeared with strong intensity in the upper left abdominal
quadrant, possibly due to stomach or intestinal fluorescence, which was confirmed in ex
vivo analysis. Several factors can decrease the ability to resolve fluorescence in vivo.
Absorption due to hemoglobin is prevalent up until 650 nm where it begins to decrease
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(Weissleder 2001). DDAO arachidonate is optimal just above this wavelength and
therefore it is possible we still face signal loss from hemoglobin absorbance. Increased
background can also result from auto-fluorescence of tissue, which is higher at lower
wavelengths (Hilderbrand and Weissleder 2010). Finally, chow fluorescence can
increase background signal resulting in loss of detectable signal. Though we attempt to
minimize the contribution of chow by feeding mice a low fluorescence diet, it is possible
this is still a contributing factor.
In vitro analysis in Chapter 4 showed that DDAO arachidonate and DDAO
palmitate are activated readily by sPLA2 GIB. Therefore, high fluorescence background
in the digestive tract is also possible through activation by pancreatic phospholipases. In
support of this, whole body fluorescence does appear to decrease at 24 and 48 hours as
probe is eliminated.
Establishment of a spectral unmixing algorithm for the separation of DDAO
fluorescence from auto-fluorescence was performed using the IVIS LivingImage
software. Upon application of the unmixing algorithm, we were able to reduce autofluorescence. Following removal of auto-fluorescence, high fluorescence remained from
intestinal fluorescence. Because DDAO fluorescence in the intestines will not be
removed through an unmixing algorithm, this implies intestinal fluorescence is a result of
activated DDAO, possibly through the actions of sPLA2 GIB, which is secreted into the
small intestine from the pancreas. Despite this, following adjustment for autofluorescence, tumor fluorescence was visualized at two hours and increased over two
days showing DDAO arachidonate can be used for tumor imaging in mice.
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The effects of intestinal signal overlap must be considered in interpreting
increased fluorescence in the tumor region of interest (ROI). It was observed that
intestinal fluorescence shifts in location over the course of two days, likely due to the
elimination of the bulk probe. By day 2, intestinal fluorescence was more closely
overlapped with the tumor and could be the cause of the increase of signal observed.
Despite this, upon quantification of the tumor ROI, we showed that DDAO
arachidonate fluorescence was significantly higher than DDAO palmitate fluorescence at
4 and 6 hours post injection (p = 0.002 and 0.02, respectively). This significance was lost
at 24 and 48 hours, possibly due to overlap with intestinal fluorescence or slow activation
of DDAO palmitate with time. Both DDAO arachidonate and DDAO palmitate
liposomes are expected to accumulate within tumors to the same degree and so we rely
on differences in activation to visualize signal. Therefore it is possible that at time points
greater than 6 hours, DDAO palmitate that is present in the tumor but not activated, may
activate through a number of mechanisms including sPLA2 and aqueous hydrolysis. The
higher rate of activation of DDAO arachidonate supports the hypotheses that this is due
to increased cPLA2 within the tumor.
After 48 hours, organs were resected and analyzed. Intestinal fluorescence was
observed to be much higher than that of tumor fluorescence, showing most of the probe is
being excreted by this time with relatively small amounts remaining in the tumor.
Fluorescence activation in the intestine is likely a result of the actions of sPLA2 GIB.
Interestingly, high fluorescence was also observable in the stomach. Though it is
possible that intestinal reflux or fecophagy could contribute to probe accumulation in the
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stomach, the low pH of the stomach should minimize this fluorescence signal. Chow
fluorescence may be an additional contributing factor to the high fluorescence seen in
stomach and intestines. Analysis of tumor fluorescence with non-digestive organs
showed significant activity from DDAO arachidonate tumor fluorescence compared to
other organs (p = 0.02, 0.03, 0.04, 0.04 for heart, lungs, kidney, and muscle respectively),
but not for DDAO palmitate. However, fluorescence intensity was low for all organs and
after 48 hours no significance was seen between DDAO arachidonate and DDAO
palmitate. These results indicate effective probe removal and relatively low tumor
delivery combined with non-selective activation with time.
Using ex vivo tumor painting experiments we were able to show that significant
activation of DDAO arachidonate versus DDAO palmitate was achievable in tumor tissue
(p = 7x 10-6). Furthermore, activity was observed on both the IVIS and Pearl Impulse
imaging systems, which is important for future research utilizing DDAO arachidonate.
A significant difference in activation could also be seen between basal-like and luminallike tumors (p = 0.001). In addition, activation was significantly greater in basal-like
tumors compared to healthy mammary fat pad (p = 0.04). These data indicate that if the
problems associated with delivery and high background can be addressed, DDAO
arachidonate could be a highly useful contrast agent for the guided surgical resection of
triple negative breast cancer.
Because DDAO arachidonate is activatable, i.v. injection may not be necessary in
a surgical procedure. Instead, similar to the ex vivo tumor painting experiments
performed, DDAO arachidonate could be painted onto tissue in the operating room. This
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would reduce the high background fluorescence seen during i.v. injection. Since rapid
activation in ex vivo studies was observed, it is likely that visualization of tumor
fluorescence would be possible at a much earlier time point using painting compared to
i.v. injection.
To test this in a model system, we inoculated mice with 4175-Luc+ cells in the
lower left mammary fat pad that lays in close proximity to the peritoneal cavity. We then
injected probe i.p. directly under the tumor. We euthanized mice after just 1 hour,
exposed the peritoneal cavity and looked for fluorescence activation. Using this
procedure, we observed high fluorescence in the tumor area relative to surrounding
cavity. Dissection of individual organs revealed that the tumor activated probe
significantly compared to surrounding mammary fat pad (p = 0.002). One mouse
displayed high fluorescence from the healthy portion of the inoculated mammary fat pad
(albeit lower than tumor fluorescence). Whether this fluorescence is a result of residual
tumor or alternative mechanisms requires further analysis. However, this highlights the
potential use of DDAO arachidonate as a surgical guide to ensure complete recession of
tissue with high cPLA2 activity. In this experiment, a shoulder tumor xenograft lying far
from the area of injection was also analyzed and shown to have significantly lower
fluorescence (p = 0.001). We repeated this experiment in mice using the luminal-like
MCF-7 cell line. Unlike the 4175-Luc+ tumors, MCF-7 tumors gave significantly less
activation in comparison (p = 0.01). However, when analyzing tumor and healthy
mammary fat pad a significant difference could still be observed (p = 0.01), suggesting
MCF-7 tumors do activate DDAO arachidonate, albeit at a much lower rate than that of
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4175-Luc+ tumors. Analysis of all organs revealed high digestive fluorescence as
observed previously. However, high levels of digestive fluorescence were also observed
in control mice. Therefore, we can contribute observed digestive fluorescence partially to
chow fluorescence. Because our measurements take place after only 1 hour of
incubation, it is likely that intestinal signal due to probe activation would increase with
time as observed previously.
Together, we conclude that DDAO arachidonate is a promising fluorophore for
the imaging of cancerous tissue in vivo and is worthy of further investigation for its use as
a contrast agent in NIR fluorescence guided surgery. DDAO arachidonate should be used
topically during surgery to visualize tumor margins and not injected i.v.. Though
alternative delivery vehicles could be explored to enhance tumor delivery, topical
delivery would also reduce the amount of probe needed, thus reducing potential systemic
side effects, and decrease the wait time needed for optimal fluorescence. Furthermore,
our results suggest DDAO arachidonate would be most useful in the NIR fluorescence
guided surgery of basal-like breast cancer. However, cPLA2 activity has been suggested
to vary in luminal-like cancers with increased expression being correlated with higher
probability of developing resistance to estrogen receptor therapy (Caiazza et al. 2011).
Therefore, use of DDAO arachidonate may be useful in staging luminal-like cancers and
serve as an indicator for patients who may eventually develop resistance. Finally,
because cPLA2 is associated with more aggressive breast cancer, DDAO arachidonate
may also be useful in analysis of tumor heterogeneity, separating more aggressive from
less aggressive tumor areas.
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CHAPTER 6: Conclusions and Future Directions
6.1

Conclusions and Potential Applications
Despite numerous discoveries related to the treatment of breast cancer, it remains

a disease with high prevalence and cancer related mortality in women (DeSantis et al.
2014). Increasing the armamentarium of available therapeutics along with developing
more sensitive imaging methods to identify and characterize breast cancer at an early
stage are both critical to increasing cure rates. Molecular based therapeutics have
emerged that target unique molecular signatures of breast cancer through both traditional
small molecule compounds and antibody-based therapeutics. Despite this, surgical
intervention remains the first line of defense for the treatment of breast cancer and the
accuracy of surgery has been shown to correlate closely with the probability of
reoccurrence and metastasis (Singletary 2002). Methods of improving surgical resection
are therefore vital to the continued treatment of this disease.
Within this dissertation, we introduced a novel activatable fluorophore, DDAO
arachidonate, selective to the breast cancer associated protein, cPLA2. Through a series
of in vitro and in vivo studies we have evaluated this probe’s specificity for cPLA2 and
for its ability to serve as a molecular imaging agent in breast cancer. Our results indicate
several advantages and potential limitations to the use of DDAO arachidonate for NIR
fluorescence guided surgery. In addition, our studies open the door for future research of
cPLA2 activity in cancer and other diseases using DDAO arachidonate. However, our
results also identify areas of concern, which will be a focus in the future design of
activatable fluorophores.
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The use of activatable probes in NIR fluorescence guided surgery deserves future
study. We have shown a high ability to distinguish healthy from cancerous tissue using
DDAO arachidonate. In addition, we have shown the ability to differentiate breast cancer
subtypes with this probe, with higher activation observed in more aggressive cancer.
Therefore, the intraoperative use of DDAO arachidonate may be able to accurately
delineate tumor margins in real-time while providing functional information on variations
in tissue heterogeneity.
DDAO arachidonate activation was shown to correlate closely with cPLA2
expression. Despite this, it was also shown that DDAO arachidonate is susceptible to
aqueous hydrolysis, sPLA2 GIB mediated hydrolysis, and possible activation through
unidentified sources. In a research setting, we proposed the use of DDAO palmitate as a
control probe to account for non-cPLA2 mediated cleavage. However, for the potential
use of DDAO arachidonate in clinical settings, this may be a confounding issue. This is
especially evident when administered i.v. We observed high background fluorescence,
partially due to activation outside the area of the tumor, especially in the digestive tract.
In addition, we saw relatively low tumor accumulation with respect to probe clearance
with the maximum measurable cPLA2 signal at 4 and 6 hours after administration. This
presents additional potential problems as the higher amounts of time necessary to
generate signal increases the likelihood of non-cPLA2 mediated cleavage.
DDAO arachidonate is an activatable fluorophore, dependent on enzymatic
cleavage for the generation of signal. Unlike non-specific and targeted fluorophores,
DDAO arachidonate does not depend to the same extent on tumor accumulation for
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enhanced signal/noise. This allows for the possible topical application of DDAO
arachidonate in a surgical setting. This would reduce the problems observed with nonspecific activation as less time would be needed between administration and
visualization. In addition, topical application would reduce the amount of probe needed
to generate contrast thus limiting potential systemic side effects, which might occur
through i.v. administration of larger concentrations. For these reasons, we believe this
mechanism of activatable fluorescence is of high value and should be utilized in the
design of future contrast agents for NIR fluorescence guided surgery.

Figure 6.1. Effects of anti-cancer drug treatment on cPLA2 activation. A) MCF-7 cells were treated
with 10 µM 5-fluorouracil, 40 µM etoposide, 10 mM phenylbutryate, or DMSO control for 12 hours.
DDAO arachidonate activation was plotted with time. B) Relative cPLA2 activity was calculated at 150
min by adjusting DDAO arachidonate activation for non-specific cleavage measured with DDAO
palmitate.
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6.2

cPLA2 Activation During Apoptosis
In our attempts to define the specificity of DDAO arachidonate, we have made

several observations related to the function of cPLA2, which warrant further
investigation. In confocal microscopy experiments presented in Chapter 4, we showed
subcellular activation of DDAO arachidonate in various cell lines. It was noted that in all
cell lines analyzed, there were a small percentage of cells that gave much higher
fluorescence than the general population. These cells were all similar in morphology in
that they were rounded up and beginning to detach from the tissue culture plastic, a
characteristic of stressed or early apoptotic cells.
cPLA2 has been previously shown to be required in TNF-α induced apoptosis
(Enari et al. 1996). Furthermore, cPLA2 has been implicated in the formation of lipid
droplets, which form in the early stages of the apoptotic response to anti-cancer therapy
(Gubern et al. 2008, Delikatny et al. 2011, Guijas et al. 2014). Therefore, if the
fluorescence that was observed in confocal microscopy was a result of cPLA2 activation
as part of the apoptotic process, then DDAO arachidonate may prove to have some utility
in measuring tumor response to therapy. Furthermore, if the high level of fluorescence
activation seen in cellular studies translates to apoptosis in tumor bearing mice, some of
the issues of signal to noise outlined earlier would be reduced.
In a preliminary study, we analyzed three apoptosis inducing agents for their
effect on DDAO arachidonate activation. We chose the MCF-7 cell line for analysis as it
contains the lowest levels of cPLA2 and therefore offers the greatest potential for
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increased signal generation. MCF-7 cells were plated in 96-well black wall, clear bottom
plates at 2.5 x 105 cells / mL in 100 µL media 24 hours prior to drug treatment. 12 hours
prior to experiment, the media was replaced with phenol red- and FBS-free media
containing 10 µM 5-fluorouracil, 40 µM etoposide, or 10 mM phenylbutyrate. Drug
concentrations for 5-fluorouracil and etoposide were chosen based on previously reported
literature values (Hernandez-Vargas et al. 2006, Alpsoy, Yasa, and Gunduz 2014). Drug
concentrations for phenylbutyrate was chosen based on previous performed toxicity
studies of the prostate cancer cell line, DU145 (Milkevitch et al. 2005, Milkevitch et al.
2007, Milkevitch, Beardsley, and Delikatny 2010). To initiate the assay, 10 µL of
DDAO arachidonate or DDAO palmitate in liposomes (MF 0.05) were added to each
well. Fluorescence was acquired with time and relative cPLA2 activity was calculated
(Figure 6.1A and B). Significant enhancement of cPLA2 activity was observed following
administration of 5-fluorouracil, etoposide, and phenylbutyrate (p = 0.02, 0.003, 0.0004,
respectively). 5-Fluorouracil, etoposide, and phenylbutyrate gave a 1.2, 1.3, and 2 fold
increase in activity, respectively, when compared to control. Together, this provides
further evidence for the role of cPLA2 in apoptosis and supports further investigation of
DDAO arachidonate for the in vivo imaging of tumor response to therapy.
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6.3

cPLA2 Involvement In Alternative Disease Models
DDAO arachidonate shows promise in its potential to serve as a contrast agent for

fluorescence guided surgery in breast cancer. We have focused on breast cancer within
this thesis for reasons including relatively high light penetration in breast tissue and
variations of cPLA2 expression levels related to breast cancer subtype. However, cPLA2
overexpression is not unique to the breast and has been observed in other cancers. In
non-small cell lung cancer, cPLA2 expression was found to be elevated in relation to
induction of the RAS oncogene (Heasley et al. 1997). In addition, it has been shown that
cPLA2 deficient mice have decreased lung tumor formation following urethane exposure

Figure 6.2. cPLA2 activity in lung cancer cell lines. A) Immunoblot of cPLA2 and GAPDH (control)
in 4175-Luc+ and three murine lung cancer lines. B) Quantification of immunoblot showing expression
relative to control. C) cPLA2 activity in 4175-Luc+ and TC1 cells as measured through activation of
DDAO arachidonate (adjusted for DDAO palmitate activation) with respect to time. Significant activity
in TC1 vs. 4175-Luc+ cells was observed (p = 2.4 x 10-7)
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(Meyer et al. 2004).
In order to explore cPLA2 in a lung cancer model, we utilized 3 murine non-small
cell lung cancer cell lines (LKR, LLC, and TC1), generously provided by Dr. Sunil
Singhal in the Department of Surgery at the University of Pennsylvania. Immunoblot of
cPLA2, carried out by Sofya Osharovich, showed a remarkable elevation in expression in
all lung cancer cell lines relative to 4175-Luc+. Most dramatic was the TC1 line, which
showed 9 fold increased expression of cPLA2 compared to the 4175-Luc+ cell line
(Figure 6.2A and B). To investigate the activity of cPLA2 within this cell line, 4175Luc+ and TC1 were plated at 2.5 x 105 and 1.25 x 105 cell/mL, respectively, in 100 µL
media. Plating concentrations were chosen to result in approximately 80% confluency at

Figure 6.3. Four step synthetic scheme for nitriloanthracenone.
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time of analysis. Following 24 hours of incubation, DDAO arachidonate or DDAO
palmitate in liposomes (MF 0.05) were added to each well. cPLA2 activity with time
was determined and data was plotted by subtraction of DDAO palmitate fluorescence
from DDAO arachidonate and scaled relative to the final number of cells (Figure 6.2C).
A significant increase of fluorescence was observed from the TC1 cell line relative to the
4175-Luc+ cell line (p = 2.4 x 10-7). Therefore, we believe non-small cell lung cancer
could be evaluated as a potential target for DDAO arachidonate mediated NIR
fluorescence guided surgery. Our preliminary results suggest lung cancers may provide
even higher levels of contrast than triple-negative breast cancer.
6.4

Second-Generation Long-Wavelength Activatable Fluorophores
Despite the success we have observed for DDAO arachidonate, signal to noise

resulting from tissue absorbance, scattering, and auto-fluorescence remain problematic.

Figure 6.4. Spectral properties of nitriloanthracenone. A) The addition of a nitrilo moiety to an
existing tricyclic fluorophore induced an 80 nm bathochromic shift in the final product. B) Fluorescence
(excitation 650 nm) results in fluorescence maximum at 680 nm and a large shoulder that persists to 750
nm, suitable for in vivo NIR imaging.
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DDAO lies at the edge of the NIR window and if fluorescence could be shifted farther
into the NIR, higher signal could potentially be acquired. Longer wavelength
fluorophores tend to be large in size, which may prevent cPLA2 mediated cleavage as
observed with naphthofluorescein diarachidonate. In addition, the structures of NIR
fluorophores typically do not allow for the caging of fluorescence. Therefore, we sought
to synthesize small tricyclic fluorophores with chemical modifications which might result
in longer wavelength fluorescence emission.
Through a four step synthesis, we introduced a nitrilo substitution to the central
ring of an anthracene scaffold to generate a fluorophore called nitriloanthracenone
(Figure 6.3). Though similar in structure to DDAO, nitriloanthracenone displayed altered
fluorescence properties, shifted further in the NIR region (Figure 6.4). Addition of the
nitrilo moiety (Figure 6.3 step 4), resulted in an 80 nm bathochromic shift of absorbance
resulting in an excitation at 650 nm, and a maximum emission at 680 nm (Figure 6.4).
The emission spectrum has a prominent shoulder which extended out to 750 nm. The
large Stokes shift in this fluorescence profile along with the extended emission
wavelength into the NIR makes nitriloanthracenone an excellent potential platform for
the design of NIR caged activatable fluorophores. Further modifications will include the
addition of dichloro and dimethoxy substituents ortho to the resonant active hydroxyl
similar to DDAO. We hypothesize that these substitutions will reduce non-specific and
aqueous hydrolysis of the esterified derivatives, a necessary characteristic in the design of
biological imaging agents. Furthermore, dichloro and dimethoxy substituents may shift
fluorescence further into the NIR to give enhanced in vivo properties. Efforts are
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currently underway to cage nitriloanthracenone to arachidonic acid in order to explore its
use for cPLA2 imaging.
6.5

Final Remarks
In conclusion, we have supplied evidence for a new molecular imaging agent

specific to cPLA2. We believe this will prove to be a valuable platform for the
exploration of the function of cPLA2 in disease progression. In breast cancer, DDAO
arachidonate warrants further investigation for its ability to aid in NIR fluorescence
guided surgery. The application of this probe to other purposes such as apoptotic
imaging or the molecular imaging of lung cancer will become clearer as more studies are
performed. Finally, second generation fluorophores, with enhanced in vivo optical
properties, offer the potential to greatly increase the capabilities of molecular imaging.
Taken together, we believe the future of activatable fluorophores is bright.
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